[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 168
1. Vishnevsiĭ EL, Loran OB, Saenko VS: [Sympathic hyperactivity and reservoir function of the bladder in men]. Urologiia; 2010 Sep-Oct;(5):57-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Group 2 patients (n = 23) with prostatic adenoma have undergone uroflowmetric monitoring before and after treatment with doxasozine (640 uroflowgrams).
  • It may be a humoral process mediated by vasoconstriction and disorder of vesical blood flow.
  • [MeSH-minor] Adrenergic alpha-Antagonists / administration & dosage. Aged. Aged, 80 and over. Heart Rate / drug effects. Humans. Male. Middle Aged. Organ Size / drug effects. Prostatic Hyperplasia / drug therapy. Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / physiopathology

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21254643.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists
  •  go-up   go-down


2. Danilov VV, Elisseva EV, Vasil'chenko AV: [Tadenan treatment of prostatic adenoma]. Urologiia; 2009 Mar-Apr;(2):68, 70-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tadenan treatment of prostatic adenoma].
  • Tadenan, a drug of plant origin, was given to 27 patients with documented prostatic adenoma for 3-12 months.
  • [MeSH-major] Plant Extracts / administration & dosage. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526878.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Fatty Alcohols; 0 / Plant Extracts; 0 / Tadenan
  •  go-up   go-down


3. Zmerli S: [My life in urology]. Tunis Med; 2008 Nov;86(11):949-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Mon vécu de l'urologie.
  • If urinary lithiasis, prostate adenoma, bladder tumor and urethra stricture constituted the majority of my activity, many other diseases specific to the Maghreb should be mentioned such as fistula between bladder and vaginal arising after obstetrical maneuvers and hydatid cyst of the kidney.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19213482.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Autobiography; Biography; English Abstract; Historical Article; Journal Article
  • [Publication-country] Tunisia
  • [Personal-name-as-subject] Zmerli S
  •  go-up   go-down


Advertisement
4. Trapeznikova MF, Dutov VV, Dolgovq AG, Urenkov SB: [Prostamol-Uno treatment in patients with prostatic adenoma and chronic non-infectious prostatitis]. Urologiia; 2008 Sep-Oct;(5):39-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostamol-Uno treatment in patients with prostatic adenoma and chronic non-infectious prostatitis].
  • We studied efficacy and safety of prostamol-Uno (PU) monotherapy in patients with prostatic adenoma (PA) comorbid with chronic abacterial prostatitis (CAP) in a clinical open trial including 45-year-old males aged over 45 years with PA comorbid with CAP, having irritative and obstructive symptoms by IPSS above 8 points and duration 6 months or longer, by NIH-CPSI above 10 points and duration 3 months or longer.
  • The patients had Qmax from 5 to 15 ml/s, urine volume 100-350 ml, residual urine volume under 150 ml, prostate size more than 25 cm3, PSA level under 4 ng/ml and no bacterial growth in the third urine portion seeding and/or prostatic secretion.
  • The effect was assessed by the disease history, complaints, digital rectal examination of the prostate, the disease symptoms by IPSS, quality of life (QoL), NIH-CPSI, bacteriological tests of the urine and prostatic secretion, urinalysis, Nechiporenko test in 3 urine portions.
  • Uroflowmetry, ultrasonic investigation of the urinary bladder and prostate, transrectal energy dopplerography of the prostate, PSA assay in the blood serum were made in all the patients.
  • Spectral doppler examination detected improvement in prostatic blood flow after PU treatment in 16 (53.3%) patients.
  • Thus, PU effectively reduces irritative and obstructive symptoms typical for prostatic adenoma in combination with CAP.
  • [MeSH-major] Plant Extracts / administration & dosage. Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy
  • [MeSH-minor] Blood Pressure / drug effects. Chronic Disease. Electrocardiography. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Quality of Life. Urination / drug effects


5. Weissbach L, Ebert T, Schmitz-Dräger B: [Taking stock after 400 days: the effects on ambulatory care from a medical point of view]. Z Arztl Fortbild Qualitatssich; 2006;100(1):40-3; discussion 44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Taking the contract signed with the AOK Bavaria and comprising the integrated care of patients with prostate carcinoma, prostate adenoma and prostatitis as an example the contents and consequences of this agreement will be described.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16524229.001).
  • [ISSN] 1431-7621
  • [Journal-full-title] Zeitschrift für ärztliche Fortbildung und Qualitätssicherung
  • [ISO-abbreviation] Z Arztl Fortbild Qualitatssich
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Gorilkovskiĭ LM, Zingerenko MB: [Efficacy and safety of tulosine in patients with prostatic adenoma]. Urologiia; 2009 Mar-Apr;(2):60, 62-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and safety of tulosine in patients with prostatic adenoma].
  • The study of tulosine (tamsulosine) efficacy and safety was made in 92 patients with lower urinary tract symptoms (LUTS) due to prostatic adenoma (PA).
  • Ultrasound investigation found no significant changes in the adenoma size.
  • Thus, tulosine is a safe and effective drug for treatment of prostatic adenoma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Prostatic Hyperplasia / drug therapy. Sulfonamides / administration & dosage. Sulfonamides / adverse effects

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526876.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Sulfonamides; G3P28OML5I / tamsulosin
  •  go-up   go-down


7. Sevriukov FA, Puchkin AB, Krupin VN, Chebykin AV, Sorokin DA, Karpukhin IV, Malinina OIu, Zorin DG: [Transurethral electrosurgery of a new generation (TURis) in the treatment of the lower urinary tract and prostate diseases]. Urologiia; 2007 May-Jun;(3):28-32, 35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transurethral electrosurgery of a new generation (TURis) in the treatment of the lower urinary tract and prostate diseases].
  • Surgical interventions were made in 175 patients aged 23-87 years (mean age 64.8 years) with different diseases of the lower urinary tract (adenoma, prostatic cancer, cancer of the urinary bladder, etc.) with application of a new generation of endoscopic technique--transurethral resection in saline (TURis system) with a generator UES-40 SurgMaster (Olympus).
  • The size of the prostate in prostatic adenoma ranged from 4.8 to 121 cm3 (mean 62.5 cm3), residual urine--92.3 ml (42.6 to 310.2 ml).
  • Mean amount of the resected tissue in sclerosis of urinary bladder cervix was 7 g (5-11 g), in prostatic adenoma--41 g (10-85 g), prostatic cancer--27 g (17-49 g).
  • Incontinence was observed in 7 (5.3%) patients after removal of urethral catheter, in 5 (3.8%) patients it stopped spontaneously to the time of discharge from the hospital, 2 (1.5%) patients with prostatic cancer retained partial orthostatic incontinence.
  • Standard time limitation for transurethral resection (60-90 min) becomes insignificant in using isotonic irrigation allowing urologists to resect safely larger adenomas than it was possible earlier.
  • [MeSH-major] Electrosurgery / methods. Prostatic Diseases / surgery. Urinary Tract / surgery. Urologic Diseases / surgery. Urologic Surgical Procedures, Male / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Humans. Male. Middle Aged. Transurethral Resection of Prostate / instrumentation. Transurethral Resection of Prostate / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17724828.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


8. Byun SS, Jeong H, Jo MK, Lee E: Relative proportions of tissue components in the prostate: are they related to the development of symptomatic BPH in Korean men? Urology; 2005 Sep;66(3):593-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relative proportions of tissue components in the prostate: are they related to the development of symptomatic BPH in Korean men?
  • OBJECTIVES: To investigate the high prevalence of lower urinary tract symptoms in Korean men with a small prostate, we studied the proportions of histologic components of prostatic adenoma in patients with symptomatic benign prostatic hyperplasia.
  • METHODS: Prostatic adenoma specimens were obtained from men with symptomatic benign prostatic hyperplasia who underwent open prostatectomy or transurethral resection of the prostate.
  • Patients were divided into three groups according to the prostate volume as measured by preoperative transrectal ultrasonography (group 1, 20 to 40 cm3, 21 men; group 2, 41 to 80 cm3, 22 men; and group 3, greater than 80 cm3, 23 men).
  • The proportion of the stroma in the prostatic adenoma and the proportions of smooth muscle, collagen types I, II, III, and V, fibronectin, and laminin in stromal tissue were determined using automatic image analyzer quantitatively.
  • RESULTS: The proportions of the stroma in the prostatic adenoma specimens of groups 1 and 2 were significantly greater than in group 3 (P < 0.05).
  • The relative smooth muscle proportion in the prostatic adenoma (proportion of stroma x proportion of smooth muscle in stromal tissue) in groups 1 and 2 was significantly greater than in group 3 (P < 0.05).
  • CONCLUSIONS: These results suggest that the dynamic component of bladder outlet obstruction, which is mediated by smooth muscle tone, may play a more important role in the development of symptomatic benign prostatic hyperplasia in Korean men.
  • [MeSH-major] Prostatic Hyperplasia / pathology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140084.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Prada Gómez PJ, de la Rua Calderón A, Romo Fonseca I, Evia Suárez M, Abascal García JM, Juan Rijo G, Fernández García J, González Sancho JM, Abascal García R, Rodríguez-Fernández R: High dose brachytherapy (real time) in patients with intermediate- or high-risk prostate cancer: technical description and preliminary experience. Clin Transl Oncol; 2005 Oct;7(9):389-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose brachytherapy (real time) in patients with intermediate- or high-risk prostate cancer: technical description and preliminary experience.
  • INTRODUCTION: It has been well documented that the outcome of prostate cancer treatment depends on the dose administered.
  • Between June 1998 and December 2004, 100 patients with adenoma of the prostate were treated with 46 Gy of external irradiation to the pelvis and 2 HDR brachytherapy fractions (each of 1150 cGy) at the end of weeks 1 and 3 of a 5-week radiotherapy course.
  • CONCLUSIONS: The good results of local control, disease-free survival and few complications that the external radiotherapy combined with HDR brachytherapy have shown suggest that the method should be considered as first-choice in the treatment of prostate tumours of high- and intermediate-risk.
  • [MeSH-major] Brachytherapy / methods. Prostatic Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Disease-Free Survival. Follow-Up Studies. Humans. Male. Postoperative Complications. Prostate / pathology. Prostate / radiation effects. Prostate / surgery. Radiotherapy Dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Dec 1;33(5):1019-27 [7493828.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1048-55 [15001244.001]
  • [Cites] Urol Clin North Am. 2001 Aug;28(3):555-65 [11590814.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1035-41 [9169810.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 1):528-34 [11792912.001]
  • [Cites] Urology. 2003 Jul;62(1):86-91; discussion 91-2 [12837428.001]
  • [Cites] Radiother Oncol. 2000 Dec;57(3):273-8 [11104885.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1646-9 [15073852.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Dec 1;33(5):1257-63 [7493850.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Apr 1;38(1):73-81 [9212007.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):525-33 [9635698.001]
  • [Cites] Arch Esp Urol. 2005 Apr;58(3):213-26; discussion 224 [15906615.001]
  • [Cites] J Urol. 2004 Sep;172(3):910-4 [15310996.001]
  • [Cites] J Urol. 2003 Mar;169(3):974-9; discussion 979-80 [12576825.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Aug 30;33(1):161-71 [7543891.001]
  • [Cites] Radiother Oncol. 1997 Sep;44(3):237-44 [9380822.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):81-90 [11777625.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):47-54 [8270459.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):823-32 [10705002.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):359-71 [8420886.001]
  • [Cites] Arch Esp Urol. 1999 Jan-Feb;52(1):32-8; discussion 38-9 [10101885.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Sep;21(4):935-9 [1917622.001]
  • [Cites] Arch Esp Urol. 1998 Nov;51(9):890-6 [9887562.001]
  • [Cites] Urol Clin North Am. 1993 Nov;20(4):713-25 [7505980.001]
  • [Cites] Urology. 1989 Jul;34(1):1-9 [2749951.001]
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23 ):3904-11 [11099319.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jul 15;35(5):875-9 [8751395.001]
  • [Cites] N Engl J Med. 1997 Jul 31;337(5):295-300 [9233866.001]
  • (PMID = 16238973.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


10. Shaplygin LV, Sivakov AA: [Use of cernilton in the therapy of prostatic adenoma and chronic prostatitis]. Urologiia; 2007 May-Jun;(3):35-7, 39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of cernilton in the therapy of prostatic adenoma and chronic prostatitis].
  • A conservative therapy with cernilton was given to 72 patients with chronic prostatitis and prostatic adenoma of stage I-II.
  • Detailed urologic examination before the treatment and after it demonstrates that cernilton is effective, safe and well tolerated medicine for prostatic adenoma and chronic prostatitis.
  • Cernilton is recommended for wider use in the treatment of patients with prostatic adenoma and chronic prostatitis.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Plant Extracts / therapeutic use. Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy

  • Genetic Alliance. consumer health - Prostatitis.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17722618.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Plant Extracts; 8054-43-1 / cernilton
  •  go-up   go-down


11. Tkachuk VN, Al'-Shukri SKh, Tkachuk IN, Mosoian MS: [Efficacy and safety of combined treatment of prostatic adenoma with 5-alpha reductase and alpha-adrenoblockers]. Urologiia; 2009 Nov-Dec;(6):25-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and safety of combined treatment of prostatic adenoma with 5-alpha reductase and alpha-adrenoblockers].
  • Pharmacotherapy of prostatic adenoma is based in present-day practice primarily on two basic groups of medicines--inhibitors of 5alpha-reductase and blockers of alphal-adrenoreceptors.
  • Our trial included 98 patients with prostatic adenoma aged 59-79 years given combined treatment with finasteride (inhibitor of 5alpha-reductase) made in Hungary (prosteride, Gedeon Richter) and an uroselective blocker of alpha1-adrenoreceptors sonisin (Gedeon Richter, Hungary).
  • After 12-month combined treatment symptoms of the disease reduced by IPSS from 17.9 +/- 1.8 to 3.9 +/- 0.9 points, Qmax rose from 8.8 +/- 0.3 to 14.6 +/- 0.3, residual urine volume diminished from 91.7 +/- 8.5 to 31.7 +/- 4.4, the size of the prostate reduced from 72.4 +/- 2.9 to 50.6 +/- 3.7, quality of life improved 2-fold.
  • Combined administration of finasteride (prosteride) and alpha1-adrenoblocker tamsulosine (sonisine) meet three principles of pharmacotherapy of prostatic adenoma: prevents progression of the disease and surgical treatment, relieves symptoms and improves quality of life.
  • [MeSH-major] 5-alpha Reductase Inhibitors. Adrenergic alpha-Antagonists / administration & dosage. Finasteride / administration & dosage. Prostatic Hyperplasia / drug therapy. Sulfonamides / administration & dosage

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • Hazardous Substances Data Bank. FINASTERIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169718.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Adrenergic alpha-Antagonists; 0 / Enzyme Inhibitors; 0 / Sulfonamides; 57GNO57U7G / Finasteride; G3P28OML5I / tamsulosin
  •  go-up   go-down


12. Vinarov AZ, Aliaev IuG, Apolikhin OI, Mazo EB, Darenkov SP, Demidko IuL, Lokshin KL, Medvedev AA, Permiakova OV, Spivak LG, Shkol'nikov ME: [Results of three-year clinical study of prostamol uno efficacy and safety in patients with initial symptoms of prostatic adenoma and risk of its progression]. Urologiia; 2010 Nov-Dec;(6):3-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of three-year clinical study of prostamol uno efficacy and safety in patients with initial symptoms of prostatic adenoma and risk of its progression].
  • PU was given in a single daily dose 320 mg for 36 months to 50 patients with initial symptoms of prostatic adenoma (PA) in comparison with 50 matched controls.
  • Administration of PU significantly increased urinary flow rate though in the controls urinary flow rate decreased, size of the prostate diminished and increased, respectively.
  • [MeSH-major] Plant Extracts / therapeutic use. Prostatic Hyperplasia / drug therapy
  • [MeSH-minor] Disease Progression. Humans. Male. Middle Aged. Organ Size. Prostate / drug effects. Prostate / ultrasonography. Prostate-Specific Antigen / blood. Quality of Life. Risk. Treatment Outcome. Urinary Bladder / physiopathology. Urinary Bladder / ultrasonography. Urinary Retention / etiology. Urinary Retention / physiopathology. Urinary Retention / prevention & control. Urodynamics / drug effects

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21433319.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Plant Extracts; 0 / Prostamol-Uno; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


13. Krivoborodov GG, Mazo EB, Efremov NS: [Temporary stent--CoreFlow Soft Stent--for diagnosis of the causes of incomplete bladder emptying in men with neurological diseases]. Urologiia; 2009 Jan-Feb;(1):13-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Temporary stent--CoreFlow Soft Stent--for diagnosis of the causes of incomplete bladder emptying in men with neurological diseases].
  • The new device--CoreFlow Soft Stent--was used for diagnosis of causes of incomplete bladder emptying (IBE) in 19 men with neurogenic diseases.
  • Group 1 consisted of 8 men with IBE and prostatic adenoma.
  • Group 2 consisted of 11 men with IBE but no prostatic adenoma.
  • Different active lengths of the stent are available to match it to the length of the prostatic urethra.
  • The introducer part was then separated from the stent part positioned in the prostatic urethra.
  • Out of 8 patients with prostatic adenoma and neurogenic diseases 4 could urinate with the stent part positioned in the prostatic urethra indicating that prostatic adenoma was the cause for IBE.
  • Our experience indicates that CoreFlow Soft Stent is a simple device for diagnosis of the causes of IBE in men with neurogenic diseases.
  • [MeSH-major] Stents. Urinary Bladder, Neurogenic / diagnosis. Urinary Retention / diagnosis
  • [MeSH-minor] Aged. Humans. Male. Middle Aged. Prostatic Hyperplasia / diagnosis. Prostatic Hyperplasia / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432228.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


14. Tarasov NI, Izmaĭlov RI: [Efficacy of combined treatment of large prostatic adenoma with doxasozine and finasteride]. Urologiia; 2009 Sep-Oct;(5):40-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of combined treatment of large prostatic adenoma with doxasozine and finasteride].
  • Combined treatment with doxasozine and finasteride was performed for 7.26 months in 38 patients with large-size prostatic adenoma (89.54 +/- 11.64 cm3).
  • The control group (28 patients with large prostatic adenoma) received surgical treatment alone.
  • Thus, combined treatment with doxasozine and finasteride can be the first-line treatment in patients with large prostatic adenoma.
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Doxazosin / administration & dosage. Enzyme Inhibitors / administration & dosage. Finasteride / administration & dosage. Prostatectomy. Prostatic Hyperplasia / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • Hazardous Substances Data Bank. FINASTERIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20209869.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Enzyme Inhibitors; 57GNO57U7G / Finasteride; NW1291F1W8 / Doxazosin
  •  go-up   go-down


15. Weizer AZ, Shah RB, Lee CT, Gilbert SM, Daignault S, Montie JE, Wood DP Jr: Evaluation of the prostate peripheral zone/capsule in patients undergoing radical cystoprostatectomy: defining risk with prostate capsule sparing cystectomy. Urol Oncol; 2007 Nov-Dec;25(6):460-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the prostate peripheral zone/capsule in patients undergoing radical cystoprostatectomy: defining risk with prostate capsule sparing cystectomy.
  • OBJECTIVES: Prostate capsule sparing cystectomy has been performed in conjunction with orthotopic diversion to preserve sexual function and improve urinary control.
  • Because concerns remain regarding incomplete surgical resection, we evaluated the risk of urothelial and prostate cancer in a series of patients undergoing radical cystoprostatectomy.
  • METHODS: A total of 35 men undergoing radical cystoprostatectomy (August 2003-August 2005) had separate submission of the prostate peripheral zone/capsule from the prostate adenoma and bladder after surgery.
  • These specimens were evaluated for bladder and prostate cancer grade, stage, and largest diameter of prostate cancer.
  • Clinical variables were compared between patients with and without carcinoma involving the prostate using standard statistical software.
  • RESULTS: Of patients, 57% had cancer involving the prostate at radical cystoprostatectomy.
  • There were 9 patients (26%) who had urothelial carcinoma involving the prostate; only prostatic urethral biopsy identified these patients before radical cystoprostatectomy.
  • Prostate adenocarcinoma was evident in 16 of 35 (47%) patients, with a majority involving the prostate peripheral zone/capsule (43%).
  • There were 4 patients (11%) who had clinically significant prostate cancer (Gleason sum >6 or tumor volume >0.5 cm(3)).
  • Patients with prostate cancer were significantly older than patients without prostate cancer (P = 0.01).
  • CONCLUSIONS: No clinical variable can confidently predict patients with prostate cancer involving the prostate.
  • Because a majority of patients undergoing radical cystoprostatectomy have cancer involving their prostate, preoperative evaluation with prostatic urethral and prostate biopsy may be useful to guide patient selection for prostate capsule sparing cystectomy.
  • [MeSH-major] Cystectomy / methods. Prostate / pathology. Prostatectomy / methods. Prostatic Neoplasms / surgery. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18047952.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


16. Ruszat R, Wyler S, Seifert HH, Reich O, Forster T, Stief CG, Sulser T, Bachmann A: [Photoselective vaporization of the prostate: experience with prostate adenomas &gt;80 cm3]. Urologe A; 2006 Jul;45(7):858-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Photoselective vaporization of the prostate: experience with prostate adenomas >80 cm3].
  • [Transliterated title] Photoselektive Vaporisation der Prostata: Erfahrungen mit Prostataadenomen >80 cm3.
  • BACKGROUND: We report about our experiences with photoselective vaporization of the prostate (PVP) in patients with symptomatic benign prostatic hyperplasia (BPH) and total prostate volume larger than 80 cm(3).
  • PATIENTS AND METHODS: The study included 201 patients with BPH: 51 (25.4%) patients had a prostate volume larger than 80 cm(3) and 150 (74.6%) patients had a volume smaller than 80 cm(3) in the preoperative transrectal ultrasound.
  • In patients with large adenomas peak urinary flow increased by 135, 136, and 132% after 6, 12, and 24 months, respectively.
  • [MeSH-major] Laser Therapy / statistics & numerical data. Prostatectomy / statistics & numerical data. Prostatic Hyperplasia / epidemiology. Prostatic Hyperplasia / surgery. Risk Assessment / methods. Urinary Incontinence / epidemiology. Urinary Incontinence / prevention & control


17. Traore CB, Kamate B, Toure ML, Diarra T, Bayo S: [Anatomopathologic, clinical and radiologic aspects of benign tumors of the prostate in Mali, 759 cases]. Mali Med; 2006;21(4):32-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anatomopathologic, clinical and radiologic aspects of benign tumors of the prostate in Mali, 759 cases].
  • [Transliterated title] Aspects anatomopathologiques, cliniques et radiologiques des tumeurs benignes de la prostate au Mali, a propos de 759 cas.
  • The benign prostate tumours are dominated by prostatic adenomyoma.
  • The objective of this work is to describe the anatomo-pathological, clinical and radiological aspects of benign prostate tumours in Mali.
  • It has involved 759 patients who had histological confirmed prostate adenoma in the Department of Urology in Point G University Hospital.
  • The patients were classified according to age, the clinical exam, the rate of prostate specific antigen (PSA), the sonogram, the macro and microscopic exam.
  • The apical part of the prostate is the area mostly involved.
  • "The night pollakiuria" was the primarily clinical sign in all patients; the prostate specific antigen (PSA) is high among more than 80%.
  • [MeSH-major] Adenomyoma / pathology. Adenomyoma / radiography. Prostatic Neoplasms / pathology. Prostatic Neoplasms / radiography. Urology Department, Hospital / statistics & numerical data
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Biopsy. Hospitals, University. Humans. Incidence. Male. Mali / epidemiology. Middle Aged. Prostate-Specific Antigen / blood. Retrospective Studies. Urination Disorders / etiology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19437843.001).
  • [ISSN] 0464-7874
  • [Journal-full-title] Le Mali médical
  • [ISO-abbreviation] Mali Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mali
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


18. Mazo EB, Sergeeva NA, Grigor'ev ME, Lebedev DV, Solov'eva EV, Konorev VA, Krovets AA: [Comparative value of molecular forms of prostate-specific antigen in diagnosis of prostatic cancer]. Urologiia; 2006 May-Jun;(3):21-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative value of molecular forms of prostate-specific antigen in diagnosis of prostatic cancer].
  • The aim of the study was to compare diagnostic significance of free PSA (fPSA)/total PSA (tPSA) versus PSA complex with alpha1-antichymotrypsin (cPSA) in tPSA level within 4-10 ng/ml in differential diagnosis of prostatic cancer (PC).
  • A complete urological examination (digital rectal test, transrectal ultrasound investigation, serum assay for fPSA and tPSA, multifocal transperineal prostatic biopsy) was made in 108 patients with tPSA blood level 4-10 ng/ ml.
  • Prostatic adenoma (PA) was histologically verified in 61 of 108 patients, fPSA/tPSA was normal.
  • A course of etiotropic therapy of chronic prostatic inflammation produced no significant changes in fPSA/tPSA and cPSA in 28 out of 39 patients.
  • Thus, cPSA in PC suspects is more informative than fPSA/tPSA in PC diagnosis.
  • CPSA in the serum depends on prostatic inflammation making difficult differential diagnosis of PC in interpretation of tPSA, fPSA/tPSA and cPSA.
  • Therefore, estimation of PSA variants and molecular forms in PC suspects and prostatic inflammation should be made after etiotropic therapy.
  • [MeSH-major] Antigens, Surface / blood. Biomarkers, Tumor / blood. Prostate-Specific Antigen / blood. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Prostatic Hyperplasia / diagnosis. Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / therapy. alpha 1-Antichymotrypsin / blood


19. Rasner PI, Pushkar' DIu: [Administration of two uroselective alpha-adrenoblockers in pharmacological treatment of acute urinary retention in patients with prostatic adenoma]. Urologiia; 2009 Nov-Dec;(6):30-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Administration of two uroselective alpha-adrenoblockers in pharmacological treatment of acute urinary retention in patients with prostatic adenoma].
  • Acute urinary retention in males is often caused by infravesical obstruction due to enlargement of the prostatic gland.
  • Recently it was found that alpha-adrenoblockers promote recovery of physiological voiding in patients with benign prostatic hyperplasia.
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Prostatic Hyperplasia / therapy. Quinazolines / administration & dosage. Sulfonamides / administration & dosage. Urinary Catheterization. Urinary Retention / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • Hazardous Substances Data Bank. ALFUZOSIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169720.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Quinazolines; 0 / Sulfonamides; 90347YTW5F / alfuzosin; G3P28OML5I / tamsulosin
  •  go-up   go-down


20. Hansel DE, Nadasdy T, Epstein JI: Fibromyxoid nephrogenic adenoma: a newly recognized variant mimicking mucinous adenocarcinoma. Am J Surg Pathol; 2007 Aug;31(8):1231-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibromyxoid nephrogenic adenoma: a newly recognized variant mimicking mucinous adenocarcinoma.
  • Nephrogenic adenomas demonstrate a variety of morphologic patterns that may occasionally be confused with malignant processes, including urothelial and prostatic carcinoma.
  • In this series, we describe 8 cases of nephrogenic adenoma that contain an admixture of the classic tubular form of nephrogenic adenoma and an unusual spindled and fibromyxoid form of nephrogenic adenoma that closely mimics infiltrating carcinoma.
  • In all cases, the classic tubular form of nephrogenic adenoma composed only a small proportion of the lesion, whereas the remainder consisted of compressed spindled cells within a fibromyxoid background, with only rare tubular and cordlike structures.
  • All 8 patients were elderly men who had a prior or concurrent history of acinar prostate cancer (n=4), combined acinar prostate and urothelial carcinoma (n=1), urothelial-type adenocarcinoma of the prostate (n=1), bladder urothelial carcinoma (n=1), or no prior reported prostatic or urothelial abnormalities (n=1).
  • Immunostains for prostate-specific antigen were negative.
  • This case series is the first report of a fibromyxoid subtype of nephrogenic adenoma.
  • Awareness of this entity and the use of ancillary techniques can aid in the diagnosis of this unusual form of nephrogenic adenoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenoma / pathology. Fibroma / pathology. Urologic Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Male. Middle Aged. Mucins / analysis. Neoplasms, Multiple Primary. Urothelium / chemistry. Urothelium / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667548.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


21. Protogerou V, Argyropoulos V, Patrozos K, Tekerlekis P, Kostakopoulos A: An alternative minimally invasive technique for large prostates (&gt;80 mL): transvesical prostatectomy through a 3-cm incision. Urology; 2010 Jan;75(1):184-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A total of 165 patients with benign prostatic hyperplasia were treated with transvesical prostatectomy through a 3-cm incision.
  • Prostate size was 85-144 cm(3) (mean 101 cm(3)).
  • Prostate adenoma was removed with finger dissection without the placement of hemostatic sutures.
  • [MeSH-major] Prostatectomy / methods. Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • [CommentIn] Urology. 2011 Mar;77(3):768; author reply 768-9 [21377027.001]
  • (PMID = 19896175.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Gorilovskiĭ LM, Zingerenko MB, Lakhno DA: [Efficacy of setegis administration after transvesical adenomectomy]. Urologiia; 2007 Nov-Dec;(6):61, 63-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The analysis of case histories of 41 patients after open TVPE for prostatic adenoma has shown that setegis (terazosin) is effective in therapy of urinary bladder overactivity which is present in the majority of patients after TVAE.
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Prazosin / analogs & derivatives. Prostatic Hyperplasia / surgery. Urination / drug effects. Urination Disorders / drug therapy. Urologic Surgical Procedures, Male

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • Hazardous Substances Data Bank. PRAZOSIN HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18649663.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 8L5014XET7 / Terazosin; XM03YJ541D / Prazosin
  •  go-up   go-down


23. Aliaev IuG, Grigorian VA, Tsarichenko DG, Lokshin KL, Kharchilava RR: [Transurethral electroresection of prostatic adenoma under transrectal ultrasonic control]. Urologiia; 2006 May-Jun;(3):8-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transurethral electroresection of prostatic adenoma under transrectal ultrasonic control].
  • The aim of the study was to improve the results of transurethral prostatic resection (TUPR) by introduction of intraoperative transrectal ultrasonic investigation (TRUSI) and to determine topographic-anatomic features of the prostate, intraorgan relations of adenomatous nodes and surgical prostatic capsule on-line in TUPR.
  • A total of 64 patients with prostatic adenoma (PA) of the second degree aged 52-79 participated in the study.
  • The patients were divided into two study groups (15 patients with volume of the prostate 36.5-78.6 cm3 and 17 patients with prostate size 80-4-141.2 cm3) in which TRUSI was performed and two control groups (n = 14, size 34.9 to 79.2 cm3 and n = 18, size 81.7-130.8 cm3, respectively) who have not undergone intraoperative TRUSI.
  • Control TRUSI on day 7 after TUPR registered mean volume of the prostate to be 19.3 +/- 1.4 cm3 in group 1, 39.8 +/- 2.1 cm3 in group 2, 28.1 +/- 1.6 cm3 in group 3, 47.7 +/- 3.2 cm3 in group 4.
  • Thus, intraoperative TRUSI provides information which helps the surgeon to orient in the course of surgery and minimize the threat of perforation of the prostatic capsule; minimizes intraoperative complications and enhances efficacy of radical transurethral electroresection of prostatic hyperplasia improving long-term outcomes of the operation.
  • [MeSH-major] Intraoperative Complications / prevention & control. Prostatic Hyperplasia / surgery. Prostatic Hyperplasia / ultrasonography. Transurethral Resection of Prostate. Ultrasonography / methods

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889081.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


24. Sergienko NF, Vasil'chenko MI, Begaev AI, Shchekochikhin AV, Shershnev SP, Reĭniuk OL, Lototskiĭ MM: [Acute urinary retention in prostatic adenoma]. Urologiia; 2010 Jul-Aug;(4):61-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute urinary retention in prostatic adenoma].
  • [MeSH-major] Prostatic Hyperplasia / complications. Urinary Retention / etiology
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Urinary Catheterization

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20973136.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Lectures
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


25. Shakhmachev VN: [Comparative evaluation of hemostatic methods during open adenomectomy]. Urologiia; 2010 Nov-Dec;(6):20-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The article compares effectiveness of different methods of hemostasis after transvesical adenomectomy for prostatic adenoma practiced in the world and presents original experience in surgical treatment of 224 patients with prostatic adenoma.
  • [MeSH-major] Blood Loss, Surgical / prevention & control. Hemostasis, Surgical / methods. Prostatectomy / methods. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21427988.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


26. Trapeznikova MF, Pozdniakov KV, Golubev GV, Terpigorev SA, Agel'tsov MV, Kuznetsov VE, Shvedov MIu: [Current trends in pharmacotherapy of prostatic adenoma: role of a new alpha-adrenoblocker kamiren XL in the treatment of this disease]. Urologiia; 2009 Jan-Feb;(1):35-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current trends in pharmacotherapy of prostatic adenoma: role of a new alpha-adrenoblocker kamiren XL in the treatment of this disease].
  • The aim of our study was assessment of clinical efficacy and safety of a new alpha-adrenoblocker kamiren XL in patients with prostatic adenoma (PA) with or without acute retention of urine (ARU).
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19434906.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists
  •  go-up   go-down


27. Takle M, Hjelle K, Beisland C: [Transvesical prostatectomy]. Tidsskr Nor Laegeforen; 2007 Feb 15;127(4):435-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mean operation time of patients with benign symptom-giving prostate enlargement was 88 min, blood loss during the operation was 917 mL and 50% of the patients received blood-transfusions during hospitalisation.
  • The median weight of enucleated prostate adenomas was 107 g and carcinoma(s) were incidentally found for 4 patients (7%).
  • [MeSH-minor] Adenoma / surgery. Aged. Aged, 80 and over. Carcinoma / surgery. Humans. Male. Middle Aged. Patient Satisfaction. Postoperative Complications / etiology. Prostatic Hyperplasia / surgery. Prostatic Neoplasms / surgery. Reoperation. Retrospective Studies. Surveys and Questionnaires. Urinary Incontinence / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17304271.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


28. Pavlov VN, Kazikhinurov AA, Ishemgulov RR, Mustafin AT: [Changes in microcirculation of the urinary bladder in patients with stage II prostatic adenoma depending on the treatment method]. Urologiia; 2008 Jan-Feb;(1):31-2, 34-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changes in microcirculation of the urinary bladder in patients with stage II prostatic adenoma depending on the treatment method].
  • To determine microcirculation in the wall of the urinary bladder in prostatic adenoma, we used a laser analyzer of capillary circulation LAKK-01.
  • Two groups participated in the trial: 105 males with stage II prostatic adenoma (the study group) and 25 volunteers (the control group).
  • In stage II prostatic adenoma the above microcirculation decreased to a subcritical perfusion level.
  • Significantly earlier and complete recovery of microcirculation was observed in patients who had taken cardura (Pfizer) in a dose 2 mg/day for 3 months after transurethral resection of prostatic gland.
  • Thus, 2 mg/day cardura (Pfizer) in patients with prostatic adenoma of stage II after TUR of the prostate promotes early and effective recovery of microcirculation.
  • [MeSH-major] Prostatic Hyperplasia / physiopathology. Prostatic Hyperplasia / therapy. Recovery of Function. Urinary Bladder / blood supply

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18649676.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; NW1291F1W8 / Doxazosin
  •  go-up   go-down


29. Neĭmark AI, Isaenko VI, Iakovets IaV, Simashkevich AV, Aliev RT: [Administration of afala preparation in urological practice]. Urologiia; 2009 May-Jun;(3):67-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our studies of afala in patients with prostatic adenoma demonstrate that afala reduces irritative disorders of urination.
  • Afala is indicated for prophylaxis in patients with initial stage of prostatic adenoma and as an alternative to expectation policy.
  • [MeSH-major] Antibodies / therapeutic use. Prostate / drug effects. Prostatic Hyperplasia / drug therapy. Urination Disorders / prevention & control
  • [MeSH-minor] Aged. Drug Administration Schedule. Humans. Male. Middle Aged. Organ Size / drug effects. Prostate-Specific Antigen / blood. Prostate-Specific Antigen / immunology. Quality of Life. Severity of Illness Index. Surveys and Questionnaires. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19673125.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antibodies; 0 / afala; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


30. Markov AV, Luk'ianov IV, Loran OB: [Complex therapy of irritative voiding disorders after transurethral resection of the prostate and adenomectomy]. Urologiia; 2007 Jul-Aug;(4):41-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complex therapy of irritative voiding disorders after transurethral resection of the prostate and adenomectomy].
  • Rehabilitation therapy was performed in 5 groups (n=122) of patients operated for prostatic adenoma (TUR of the prostate, transvesical prostatectomy) and having postoperative marked irritative miction disorders.
  • Thus, adjuvant physiotherapy inclusion in the complex of postoperative rehabilitation of patients operated for prostatic adenoma is justified as it improves treatment efficacy.
  • [MeSH-major] Prostatic Hyperplasia / rehabilitation. Urinary Incontinence / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy / methods. Follow-Up Studies. Humans. Male. Middle Aged. Prostate / surgery. Prostatectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Urinary Incontinence.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17915448.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


31. Verschoyle RD, Greaves P, Cai H, Edwards RE, Steward WP, Gescher AJ: Evaluation of the cancer chemopreventive efficacy of rice bran in genetic mouse models of breast, prostate and intestinal carcinogenesis. Br J Cancer; 2007 Jan 29;96(2):248-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the cancer chemopreventive efficacy of rice bran in genetic mouse models of breast, prostate and intestinal carcinogenesis.
  • We tested the hypothesis that rice bran interferes with development of tumours in TAg, TRansgenic Adenocarcinoma of the Mouse Prostate (TRAMP) or Apc(Min) mice, genetic models of mammary, prostate and intestinal carcinogenesis, respectively.
  • Consumption of rice bran reduced numbers of intestinal adenomas in Apc(Min) mice by 51% (P<0.01), compared to mice on control diet.
  • At 10% in the diet, rice bran did not significantly retard Apc(Min) adenoma development.
  • [MeSH-major] Breast Neoplasms / prevention & control. Dietary Fiber / administration & dosage. Disease Models, Animal. Intestinal Neoplasms / prevention & control. Oryza. Prostatic Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Dietary Fiber.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nutr Cancer. 1993;20(1):41-9 [8415129.001]
  • [Cites] Dig Dis Sci. 2001 Jul;46(7):1367-80 [11478486.001]
  • [Cites] Mol Nutr Food Res. 2005 Jun;49(6):571-84 [15864783.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):378-91 [15637400.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] Carcinogenesis. 1997 Oct;18(10):1863-5 [9363991.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1709-11 [15470192.001]
  • [Cites] Oncol Rep. 2003 Jul-Aug;10(4):875-80 [12792738.001]
  • [Cites] Nutr Cancer. 2004;49(2):170-3 [15489210.001]
  • [Cites] Am J Epidemiol. 1996 Dec 1;144(11):1015-25 [8942431.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5947-52 [7954427.001]
  • [Cites] Cell. 1989 Jul 28;58(2):249-55 [2546678.001]
  • [Cites] EMBO J. 1992 Dec;11(13):5013-20 [1464323.001]
  • [Cites] Carcinogenesis. 1999 Nov;20(11):2109-15 [10545413.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2556-60 [8653697.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6367-70 [12438216.001]
  • [Cites] N Engl J Med. 1993 May 6;328(18):1313-6 [8385741.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43 [7724580.001]
  • [Cites] Int J Oncol. 2004 Dec;25(6):1809-15 [15547721.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jun;11(6):535-40 [12050094.001]
  • [Cites] Prostate Cancer Prostatic Dis. 1999 Mar;2(2):70-75 [12496841.001]
  • [Cites] Oncol Rep. 2006 Mar;15(3):533-8 [16465408.001]
  • [Cites] Oncol Rep. 2002 Jul-Aug;9(4):817-22 [12066215.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10350-5 [11504910.001]
  • [Cites] Carcinogenesis. 2000 Jun;21(6):1167-73 [10837006.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):215-24 [12824459.001]
  • [Cites] Chem Pharm Bull (Tokyo). 1988 Sep;36(9):3609-13 [3240551.001]
  • [Cites] Cancer Chemother Rep. 1966 May;50(4):219-44 [4957125.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11236-40 [7972041.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88 [9747868.001]
  • [Cites] Br J Cancer. 1998;77(1):1-10 [9459138.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5040-4 [11016626.001]
  • [Cites] Carcinogenesis. 2000 May;21(5):921-7 [10783313.001]
  • [Cites] Am J Clin Pathol. 1954 Sep;24(9):1016-24 [13197333.001]
  • [Cites] J Nutr. 1993 Nov;123(11):1939-51 [8229312.001]
  • (PMID = 17211473.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0100874
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2359993
  •  go-up   go-down


32. Razumov SV, Egorov AA: [Expediency of switching from combined therapy with prostamol Uno and alpha-1-adrenoblockers to monotherapy with prostamol Uno in patients with prostatic adenoma]. Urologiia; 2007 May-Jun;(3):47-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expediency of switching from combined therapy with prostamol Uno and alpha-1-adrenoblockers to monotherapy with prostamol Uno in patients with prostatic adenoma].
  • A total of 58 patients with prostatic adenoma (PA) treated with prostamol Uno in combination with tamsulosin were divided into two groups: 28 patients continued the above combined therapy, 30 patients were switched to monotherapy with prostamol Uno.
  • All the patients were examined in the course of 4 visits according to standard protocol requesting information on the disease history, complaints, digital rectal examination, IPSS questionnaire, QOL, uroflowmetry with test for residual urine, transrectal ultrasonography of the prostate, blood test for PSA.
  • To the end of treatment month 9 the size of the prostate diminished by 6.7 cm3, on the average, in both groups.
  • [MeSH-major] Adrenergic alpha-1 Receptor Antagonists. Adrenergic alpha-Antagonists. Plant Extracts. Prostatic Hyperplasia / drug therapy
  • [MeSH-minor] Aged. Drug Administration Schedule. Drug Therapy, Combination. Humans. Male. Middle Aged. Prostate-Specific Antigen / analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17724829.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-1 Receptor Antagonists; 0 / Adrenergic alpha-Antagonists; 0 / Plant Extracts; 0 / Prostamol-Uno; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


33. Ergakov DV, Martov AG, Maksimov VA: [Improvement of surgical outcomes in patients with prostatic adenoma due to postoperative administration of the drug likoprofit]. Urologiia; 2009 Jan-Feb;(1):24-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Improvement of surgical outcomes in patients with prostatic adenoma due to postoperative administration of the drug likoprofit].
  • We studied efficacy and safety of likoprofit pharmacotherapy in patients early after transurethral resection (TUR) of the prostate.
  • Likoprofit showed high efficacy early after TUR for prostatic adenoma in correction of irritative disorders of urination (frequent voiding, urges, painful urination with small urine portions).
  • [MeSH-major] Phytotherapy. Plant Preparations / administration & dosage. Postoperative Care. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432230.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Plant Preparations
  •  go-up   go-down


34. Barrier F, de La Guerenne A, Semjen E, Wierre L, Horrent S, Decaudin B, Resibois JP, Weillaert MP, Azar R, Odou P: [Spontaneously acquired haemophilia: report of a patient with prostatic adenoma]. Ann Biol Clin (Paris); 2006 Jul-Aug;64(4):347-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Spontaneously acquired haemophilia: report of a patient with prostatic adenoma].
  • [Transliterated title] Hémophilie A acquise secondaire à un adénome prostatique.
  • Two diagnosis were suspected: a coagulation factor defect, or the presence of a lupus anticoagulant or of anti-factor antibodies.
  • A prostatic adenocarcinoma was suspected: a 5 cm prostatic tumour was found and the PSA level was 113 ng/mL.
  • The patient's disease was identified as a spontaneously acquired haemophilia A associated with prostatic adenocarcinoma.
  • [MeSH-major] Adenoma / complications. Hemophilia A / etiology. Prostatic Neoplasms / blood. Prostatic Neoplasms / complications
  • [MeSH-minor] Aged, 80 and over. Anemia / etiology. Diagnosis, Differential. Factor VIII / analysis. Hematoma. Humans. Male. Prostate-Specific Antigen / blood. Triazines

  • MedlinePlus Health Information. consumer health - Hemophilia.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16829479.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Triazines; 55824-91-4 / 4-azido-7-phenylpyrazolo-(1,5a)-1,3,5-triazine; 9001-27-8 / Factor VIII; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


35. Teodorovich OV, Zabrodina NB, Bochkarev AB: [Using setegis (terasosine) in early postoperative period after transurethral prostate resection]. Urologiia; 2009 May-Jun;(3):62-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Using setegis (terasosine) in early postoperative period after transurethral prostate resection].
  • TUR of the prostatic gland for prostatic adenoma was made in 93 patients aged 54-81 years (mean age 64.4 +/- 7.5 years).
  • Thus, terasosine (setegis) can be recommended for use in early postoperative period after TUR of the prostate for prostatic adenoma as an effective and safe drug improving postoperative outcome.
  • [MeSH-major] Adrenergic alpha-Antagonists / therapeutic use. Prazosin / analogs & derivatives. Prostatic Hyperplasia / drug therapy. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate. Urination Disorders / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • Hazardous Substances Data Bank. PRAZOSIN HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19673124.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 8L5014XET7 / Terazosin; XM03YJ541D / Prazosin
  •  go-up   go-down


36. Kogan MI, Kireev AIu: [The questionnaire of integral assessment of male sexuality]. Urologiia; 2009 Jan-Feb;(1):46-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The proposed questionnaire can serve as a tool for studies of male sexuality in relation with different pathological processes: prostatic adenoma and cancer, metabolic syndrome, erectile dysfunction and others.

  • MedlinePlus Health Information. consumer health - Sexual Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432233.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


37. Józsa LG: Histologic diagnoses of tissues from two nineteenth century Habsburgs. Paleopathol Newsl; 2008 Mar;(141):12-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gout (urate nephropathy), severe arteriosclerosis, prostate adenoma and purulent prostatitis could also be diagnosed.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18831390.001).
  • [ISSN] 0148-4737
  • [Journal-full-title] Paleopathology newsletter
  • [ISO-abbreviation] Paleopathol Newsl
  • [Language] eng
  • [Publication-type] Biography; Historical Article; Journal Article
  • [Publication-country] United States
  • [Personal-name-as-subject] Habsburg J; Romanova AP
  •  go-up   go-down


38. Likhin FA, Bartnovskiĭ AE, Vdovichenko KK, Abramov AA, Belokhvostov AS: [Characteristics of methyl-specific PCR-test of glutathione-S-transferase P1 gene in plasm DNA and cellular urinary precipitate for differential diagnosis of prostatic adenoma and adenocarcinoma]. Urologiia; 2005 Jul-Aug;(4):12-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characteristics of methyl-specific PCR-test of glutathione-S-transferase P1 gene in plasm DNA and cellular urinary precipitate for differential diagnosis of prostatic adenoma and adenocarcinoma].
  • The study was made of possibilities of methyl-specific PCR-test of glutathione-S-transferase P1 (GSTP1) gene in differential diagnosis of prostatic cancer: sensitivity of the test, comparison of reagents of Russian and foreign production.
  • Blood plasm and cellur urinary precipitate DNA was investigated in patients with prostatic adenocarcinoma.
  • The results show that the above test with domestic reagents is rather perspective for differential diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. DNA, Neoplasm / analysis. Polymerase Chain Reaction / methods. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] DNA / blood. DNA / metabolism. DNA / urine. DNA Methylation. Diagnosis, Differential. Humans. Male. Prostatic Hyperplasia / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16158738.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 9007-49-2 / DNA
  •  go-up   go-down


39. Cossu-Rocca P, Contini M, Brunelli M, Festa A, Pili F, Gobbo S, Eccher A, Mura A, Massarelli G, Martignoni G: S-100A1 is a reliable marker in distinguishing nephrogenic adenoma from prostatic adenocarcinoma. Am J Surg Pathol; 2009 Jul;33(7):1031-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S-100A1 is a reliable marker in distinguishing nephrogenic adenoma from prostatic adenocarcinoma.
  • Nephrogenic adenoma is a benign lesion that may occur at any site of the genitourinary tract, usually in association with previous urothelial injuries.
  • In addition to its uncertain origin, there can be diagnostic difficulty in distinguishing nephrogenic adenoma from prostatic adenocarcinoma, particularly with lesions arising in the prostatic urethra.
  • Alpha-methylacyl-CoA racemase (AMACR), a recently identified prostate cancer marker, has also been found to be expressed in renal tubules and in some renal epithelial neoplasms.
  • In this study, we investigated the expression of S100A1 and AMACR in 18 nephrogenic adenomas and in 100 prostatic adenocarcinomas.
  • A strong and distinct cytoplasmic or nucleocytoplasmic staining of S100A1 was found in 17 out of 18 cases of nephrogenic adenoma (94%), but never in prostatic adenocarcinoma.
  • In contrast, AMACR expression was detected in 14 of 18 nephrogenic adenomas (78%) and in 96 of 100 prostatic adenocarcinomas (96%).
  • We conclude that (1) S100A1 is a specific and sensitive immunohistochemical marker to differentiate nephrogenic adenoma from prostatic adenocarcinoma;.
  • (3) given that both S100A1 and AMACR have been reported to be expressed in renal tubular cells and in a subset of renal cell neoplasms, our findings confirm the histogenetic relationship between nephrogenic adenoma and renal tubular epithelium.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Prostatic Neoplasms / diagnosis. S100 Proteins / biosynthesis. Urogenital Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Racemases and Epimerases / biosynthesis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19384190.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins; 0 / S100A1 protein; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


40. Bogdanov AB, Luk'ianov IV, Veliev EI: [Efficacy and safety of doxazosine in combination with finasteride in the treatment of prostatic adenoma]. Urologiia; 2008 Nov-Dec;(6):44-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and safety of doxazosine in combination with finasteride in the treatment of prostatic adenoma].
  • Clinical effects and safety of doxazosine + finasteride combination were studied in patients with obstructive and irritative symptoms due to prostatic adenoma (PA).
  • Lower urinary tract symptoms according to IPSS, size of the prostatic gland, Qmax and Qmid, bladder capacity, residual urine volume, blood pressure, PSA level, sexual function, side effects were assessed before and after combined use of the drugs in 30 patients aged 58 to 83 years (mean age 70.5 years).
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Doxazosin / administration & dosage. Enzyme Inhibitors / administration & dosage. Finasteride / administration & dosage. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • Hazardous Substances Data Bank. FINASTERIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19248599.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Enzyme Inhibitors; 57GNO57U7G / Finasteride; NW1291F1W8 / Doxazosin
  •  go-up   go-down


41. Chepurov AK, Bulantsev DIu: [Comparative assessment of anatomo-functional features of the vesico-urethral segment and urinary bladder before and after surgical interventions for prostatic adenoma]. Urologiia; 2007 Jan-Feb;(1):67-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative assessment of anatomo-functional features of the vesico-urethral segment and urinary bladder before and after surgical interventions for prostatic adenoma].
  • [MeSH-major] Prostatic Hyperplasia / surgery. Urethra / pathology. Urethra / physiopathology. Urinary Bladder / pathology. Urinary Bladder / physiopathology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17472005.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Number-of-references] 71
  •  go-up   go-down


42. Mariano MB, Tefilli MV, Graziottin TM, Morales CM, Goldraich IH: Laparoscopic prostatectomy for benign prostatic hyperplasia--a six-year experience. Eur Urol; 2006 Jan;49(1):127-31; discussion 131-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic prostatectomy for benign prostatic hyperplasia--a six-year experience.
  • PURPOSE: The Authors present their results using laparoscopic prostatectomy in the treatment of large benign prostatic hyperplasia (BPH).
  • RESULTS: The average prostate weight was 144.50+/-41.74 gm.
  • CONCLUSIONS: The results demonstrate that resection of large prostatic adenomas can be performed with a laparoscopic approach.
  • [MeSH-major] Laparoscopy. Prostatectomy / methods. Prostatic Hyperplasia / surgery


43. Sergienko NF, Vasil'chenko MI, Begaev AI, Shekochikhin AV, Shershnev SP, Reĭniuk OL, Lototskiĭ MM: [Transvesical extraurethral adenomectomy and transurethral prostatic resection in adenoma: specific features]. Urologiia; 2010 Sep-Oct;(5):29-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transvesical extraurethral adenomectomy and transurethral prostatic resection in adenoma: specific features].
  • The procedure of transvesical extraurethral adenomectomy (EUA) and the results of its application were characterized in comparison with transurethral resection (TUR) of the prostate in adenoma.
  • Dissection is conducted of the affected posterior half-round of only proximal prostatic part of the urethra in unaffected anterior and lateral urethral surface.
  • TUR of the prostate is made without incision of the soft tissues of the anterior abdominal wall, but with removal of the prostatic portion of the urethra, sphincter mechanism of the bladder.
  • After TUR the prostate contains residual adenomatous tissue, inner wound cavity in adenoma bed.
  • The wound of the anterior abdominal wall, anterior wall of the bladder and vesicourethral segment healed by primary intention for 10-14 days, while adenoma bed heals for 6-18 months.
  • EUA does not cause such complication as "adenoma bed", urethral stricture, scar deformation of the bladder neck, urinary incontinence.
  • Radical EUA produces complications 5 times less frequently than TUR of the prostate.
  • [MeSH-major] Prostate / surgery. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate / methods

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21260939.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


44. Bratchikov OI, Ambarian AA, Shumakova EA, Khmaruk AP, Kriukov AA, Trifonov EIu, Mikhaĭlov DV, Abduldzhalil Shukri MA: [Etiological and prognostic aspects of renal failure in patients with prostatic adenoma]. Urologiia; 2010 Jan-Feb;(1):38-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Etiological and prognostic aspects of renal failure in patients with prostatic adenoma].
  • The aim of our study was to assess the causes of renal failure in patients with prostatic adenoma (PA) and outcomes after draining of the urinary bladder.
  • We found that age, prostate volume, PA growth pattern, urinary tract infection, concomitant pathology (arterial hypertension, diabetes mellitus, atherosclerosis) do not correlate with a serum creatinine level.
  • [MeSH-major] Creatinine / blood. Prostatic Hyperplasia / complications. Renal Insufficiency / etiology

  • MedlinePlus Health Information. consumer health - Creatinine.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20886730.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  •  go-up   go-down


45. Ye H, Montgomery E, Epstein JI: Incidental anorectal pathologic findings in prostatic needle core biopsies: a 13-year experience from a genitourinary pathology consult service. Hum Pathol; 2010 Dec;41(12):1674-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental anorectal pathologic findings in prostatic needle core biopsies: a 13-year experience from a genitourinary pathology consult service.
  • Fragments of anorectal mucosa are frequently present in transrectal prostate core biopsy specimens.
  • We reviewed pathologic reports of 96,656 prostate biopsies diagnosed in our consultation service from 1997 to 2010.
  • A flat rectal adenoma with high-grade dysplasia was identified, for which the patient received hemicolectomy.
  • Other neoplastic findings included 1 with low-grade B-cell lymphoma, 3 with hyperplastic polyps, 3 with tubular adenomas, and 1 with anal mucosa with high-grade dysplasia that was found to be a contaminant from another case. (2) Inflammatory changes (n = 20).
  • In conclusion, it is exceedingly rare to find significant pathology in the rectal fragments associated with prostate needle biopsies.
  • [MeSH-major] Anus Diseases / diagnosis. Incidental Findings. Prostatic Diseases / diagnosis
  • [MeSH-minor] Adenoma / pathology. Adenoma / surgery. Aged. Biopsy, Needle. Colonic Polyps / pathology. Humans. Intestinal Mucosa / pathology. Male. Middle Aged. Referral and Consultation

  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • MedlinePlus Health Information. consumer health - Prostate Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20869745.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Manzarbeitia F, Vela Navarrete R, Fernández-Aceñero MJ: [Early histopathological aspects of benign prostatic hyperplasia: myxoid-inflammatory nodules]. Actas Urol Esp; 2010 Jun;34(6):549-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Early histopathological aspects of benign prostatic hyperplasia: myxoid-inflammatory nodules].
  • [Transliterated title] Aspectos histopatológicos iniciales de la hiperplasia benigna de próstata: nódulos mixo-inflamatorios.
  • OBJECTIVES: Infiltration of benign prostatic hyperplasia (BPH), nodular prostatic hyperplasia (NPH) or prostatic adenoma by mononuclear cells, predominantly lymphocytes, is a common finding in surgical specimens.
  • [MeSH-major] Prostatic Hyperplasia / pathology

  • Genetic Alliance. consumer health - Benign Prostatic Hyperplasia.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20510119.001).
  • [ISSN] 1699-7980
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


47. Kolbasov DN: [Hyperbaric oxygenation in patients with prostatic adenoma]. Urologiia; 2009 Mar-Apr;(2):92-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hyperbaric oxygenation in patients with prostatic adenoma].
  • [MeSH-major] Hyperbaric Oxygenation. Prostatic Hyperplasia / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526884.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Number-of-references] 41
  •  go-up   go-down


48. Pushkar' DIu, Loran OB, Petrov SB, Kogan MI, Zhuravlev VN: [Efficacy and safety of revocarin in patients with impaired micturition due to prostatic adenoma. An open non-comparative study: results of a multicenter trial]. Urologiia; 2008 Jan-Feb;(1):23, 25-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and safety of revocarin in patients with impaired micturition due to prostatic adenoma. An open non-comparative study: results of a multicenter trial].
  • Patients with impaired micturition caused by prostatic adenoma received revocarin for 12-weeks.
  • Thus, a 12-week course of revocarin demonstrated good clinical efficacy and safety in patients with urination problems because of prostatic adenoma.
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Prostatic Hyperplasia / drug therapy. Sulfonamides / administration & dosage. Urinary Retention / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18649675.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Sulfonamides; G3P28OML5I / tamsulosin
  •  go-up   go-down


49. Cho EY, Kim KM, Park CK, Kim JJ, Sohn TS, Kim DW: AMACR is highly expressed in gastric adenomas and intestinal-type carcinomas. APMIS; 2007 Jun;115(6):713-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AMACR is highly expressed in gastric adenomas and intestinal-type carcinomas.
  • Alpha-methylacyl-CoA racemase (AMACR) is a novel tumor biomarker expressed in a number of neoplasms, including colorectal and prostatic adenocarcinomas.
  • Using immunohistochemistry we studied the expression of AMACR in normal gastric mucosa (n=32), intestinal metaplasia (n=26), adenomas (n=29) and adenocarcinomas (n=132) of the stomach from 135 patients.
  • Synchronous adenocarcinomas arising in the background of adenomas were observed in 26 cases.
  • Tissue from intestinal metaplasia, adenomas, and adenocarcinomas was positive in 7.7% (2/26), 79.3% (23/29), and 62.9% (83/132) of cases, respectively.
  • The difference in AMACR expression between adenomas or adenocarcinomas and non-neoplastic mucosa was statistically significant (p=0.0001).
  • Our results indicate that as well as being an additional diagnostic tool, altered AMACR expression in gastric adenomas and intestinal-type carcinomas suggests that AMACR may be involved early in the development of intestinal-type gastric carcinomas.
  • [MeSH-major] Adenoma / metabolism. Biomarkers, Tumor / analysis. Intestinal Neoplasms / metabolism. Intestines / pathology. Racemases and Epimerases / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17550379.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


50. Bachmann A: Editorial comment on: transurethral photoselective vaporization versus transvesical open enucleation for prostatic adenomas &gt;80ml: 12-mo results of a randomized prospective study. Eur Urol; 2008 Aug;54(2):435-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Editorial comment on: transurethral photoselective vaporization versus transvesical open enucleation for prostatic adenomas >80ml: 12-mo results of a randomized prospective study.
  • [MeSH-major] Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Eur Urol. 2008 Aug;54(2):427-37 [18069117.001]
  • (PMID = 18069122.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] Switzerland
  •  go-up   go-down


51. Teodorovich OV, Shatokhin MN, Mal'tsov VN, Konoplia AI, Loktiononv AL, Krasnov AV: [Correction of local immunometabolic disturbances combined with chronic prostatitis in prostatic adenoma]. Urologiia; 2010 Sep-Oct;(5):22-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correction of local immunometabolic disturbances combined with chronic prostatitis in prostatic adenoma].
  • We compared local immunometabolic effects of two dosage forms of longidase in patients with prostatic adenoma (PA) in combination with chronic prostatitis (CP) in the postoperative period.
  • Transurethral resection (TUR) of the prostate was conducted in 81 patients aged 50-70 years suffering from PA and CP.
  • [MeSH-major] Prostatic Hyperplasia / blood. Prostatic Hyperplasia / immunology. Prostatitis / blood. Prostatitis / immunology


52. Malek RS: [Photoselective vaporization with high-performance potassium-titanil-phosphate laser in the treatment of obstructive prostatic adenoma]. Urologiia; 2006 Sep-Oct;(5):11-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Photoselective vaporization with high-performance potassium-titanil-phosphate laser in the treatment of obstructive prostatic adenoma].
  • Novel laser technologies were used in development of a new highly effective and simple method of laser adenomectomy (LA) called photoselective vaporization of the prostate (PVP).
  • Efficacy of PVP is comparable to transurethral resection (TUR) of prostatic adenoma but is more cost-effective than TUR or other low-invasive techniques.
  • Therefore, PVP is very promising in surgical treatment of obstructive prostatic adenoma and may become a leading surgical method in this disease.
  • [MeSH-major] Laser Therapy. Prostatectomy / methods. Prostatic Hyperplasia / surgery
  • [MeSH-minor] Animals. Humans. Male. Phosphates. Potassium Compounds. Transurethral Resection of Prostate / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. DIPOTASSIUM PHOSPHATE .
  • Hazardous Substances Data Bank. MONOPOTASSIUM DIHYDROGEN PHOSPHATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17444145.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Phosphates; 0 / Potassium Compounds; 16068-46-5 / potassium phosphate
  •  go-up   go-down


53. Aliaev IuG, Vinarov AZ, Lokshin KL, Spivak LG: [Extracts Serenoa repens in the treatment of prostatic adenoma and chronic abacterial prostatitis: results of short-term (3-month courses) therapy]. Urologiia; 2007 Mar-Apr;(2):80-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extracts Serenoa repens in the treatment of prostatic adenoma and chronic abacterial prostatitis: results of short-term (3-month courses) therapy].
  • [MeSH-major] Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy. Serenoa / chemistry

  • Genetic Alliance. consumer health - Prostatitis.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17578203.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Plant Extracts
  • [Number-of-references] 33
  •  go-up   go-down


54. Błaut K, Wiśniewski P, Syrenicz A, Sworczak K: Apoplexy of clinically silent pituitary adenoma during prostate cancer treatment with LHRH analog. Neuro Endocrinol Lett; 2006 Oct;27(5):569-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoplexy of clinically silent pituitary adenoma during prostate cancer treatment with LHRH analog.
  • LHRH analogs have become a promising modality in prostate cancer therapy as an alternative to surgical castration, and the use of these agents is generally considered to be safe.
  • Since now, only few cases of an apoplexy of previously undiagnosed pituitary adenoma (usually gonadotropinoma) at the beginning of therapy have been described in the medical literature.
  • We present a case of a 74 year old patient who was diagnosed of prostate cancer at the age of 68.
  • During 6 years of follow-up there was no evidence of prostate cancer recurrence.
  • [MeSH-major] Adenoma / complications. Gonadotropin-Releasing Hormone / analogs & derivatives. Neoplasms, Multiple Primary / diagnosis. Pituitary Apoplexy / etiology. Pituitary Neoplasms / complications. Prostatic Neoplasms / drug therapy


55. Laiyemo AO, Doubeni C, Pinsky PF, Doria-Rose VP, Bresalier R, Lamerato LE, Crawford ED, Kvale P, Fouad M, Hickey T, Riley T, Weissfeld J, Schoen RE, Marcus PM, Prorok PC, Berg CD: Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities. J Natl Cancer Inst; 2010 Apr 21;102(8):538-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A total of 60, 572 non-Hispanic white and black participants in the ongoing Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial underwent trial-sponsored screening flexible sigmoidoscopy (FSG) without biopsy at baseline in 10 geographically dispersed centers from November 1993 to July 2001.
  • Overall, among subjects with diagnostic colonoscopy (n = 10 424), there was no statistically significant difference by race in the prevalence of adenoma, advanced adenoma, advanced pathology in small adenomas (high-grade dysplasia or villous histology in adenomas <10 mm), or colorectal cancer.
  • [MeSH-minor] Aged. Colonoscopy. Early Detection of Cancer. Female. Genetic Predisposition to Disease. Humans. Incidence. Lung Neoplasms / prevention & control. Male. Mass Screening / methods. Mass Screening / statistics & numerical data. Middle Aged. Ovarian Neoplasms / prevention & control. Prostatic Neoplasms / prevention & control. Randomized Controlled Trials as Topic. Risk Factors. Sigmoidoscopy. Socioeconomic Factors. United States / epidemiology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - Choosing a Doctor or Health Care Service.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Health Disparities.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Epidemiol. 2007 Apr 15;165(8):874-81 [17244633.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 17;97(16):1211-20 [16106026.001]
  • [Cites] J Natl Med Assoc. 2007 Jul;99(7):723-8 [17668638.001]
  • [Cites] J Natl Med Assoc. 2007 Jul;99(7):733-48 [17668639.001]
  • [Cites] Postgrad Med J. 2007 Sep;83(983):583-9 [17823224.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Natl Med Assoc. 2008 Mar;100(3):291-8 [18390022.001]
  • [Cites] J Gen Intern Med. 2008 May;23(5):699-705 [18338215.001]
  • [Cites] J Natl Cancer Inst. 2008 Jul 16;100(14):1003-12 [18612132.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Sep;6(9):1011-5 [18558514.001]
  • [Cites] JAMA. 2008 Sep 24;300(12):1417-22 [18812532.001]
  • [Cites] Gastroenterology. 2008 Oct;135(4):1100-5 [18691580.001]
  • [Cites] J Natl Med Assoc. 2008 Dec;100(12):1441-4 [19110912.001]
  • [Cites] Arch Surg. 2009 Jan;144(1):14-8 [19153319.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2170-5 [19622721.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):162-8 [10900274.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):169-74 [10900275.001]
  • [Cites] Control Clin Trials. 2000 Dec;21(6 Suppl):251S-272S [11189683.001]
  • [Cites] Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S [11189684.001]
  • [Cites] Control Clin Trials. 2000 Dec;21(6 Suppl):379S-389S [11189689.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 7;94(15):1160-7 [12165641.001]
  • [Cites] Am J Epidemiol. 2004 Jan 15;159(2):213-4; author reply 214-5 [14718224.001]
  • [Cites] Cancer. 1986 Aug 15;58(4):997-1000 [3719563.001]
  • [Cites] Cancer Nurs. 1995 Oct;18(5):385-92 [7585493.001]
  • [Cites] Cancer. 1998 Jun 15;82(12):2312-20 [9635522.001]
  • [Cites] JAMA. 1998 Nov 18;280(19):1690-1 [9832001.001]
  • [Cites] Cell Oncol. 2007;29(3):185-94 [17452771.001]
  • [Cites] Arch Intern Med. 2005 Oct 10;165(18):2129-35 [16217003.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Aug;3(8):792-7 [16234008.001]
  • [Cites] Am J Gastroenterol. 2006 Apr;101(4):823-30 [16494591.001]
  • [Cites] Cancer. 2006 Sep 1;107(5 Suppl):1153-61 [16862554.001]
  • [Cites] Cancer. 2006 Oct 15;107(8 Suppl):2043-51 [16977600.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):612-20 [17186529.001]
  • [Cites] Am J Gastroenterol. 2005 Mar;100(3):515-23; discussion 514 [15743345.001]
  • [Cites] Am J Psychiatry. 2005 Jul;162(7):1336-43 [15994717.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 6;97(13):989-97 [15998952.001]
  • [CommentIn] J Natl Cancer Inst. 2010 Apr 21;102(8):511-3 [20357246.001]
  • (PMID = 20357245.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-25524; United States / NCI NIH HHS / CN / N01-CN-25513; United States / NCI NIH HHS / CN / N01-CN-25511; United States / NCI NIH HHS / CN / N01-CN-75022; United States / NCI NIH HHS / CN / N01-CN-25514; United States / NCI NIH HHS / CN / N01-CN-25512; United States / NCI NIH HHS / CN / N01-CN-25515; United States / NCI NIH HHS / CA / K01 CA127118; United States / NCI NIH HHS / CA / R01 CA151736; United States / NCI NIH HHS / CN / N01-CN-25404; United States / NCI NIH HHS / CN / N01-CN-25516; United States / NCI NIH HHS / CN / N01-CN-25476; United States / NCI NIH HHS / CN / N01-CN-25518; United States / NCI NIH HHS / CA / U01 CA151736; United States / NCI NIH HHS / CN / N01-CN-25522
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2857802
  •  go-up   go-down


56. Cohen RJ, Shannon BA: Tubulovillous adenoma of the prostatic urethra: a rare and usually indolent lesion distinct from prostatic adenocarcinoma. Pathology; 2007 Oct;39(5):522-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubulovillous adenoma of the prostatic urethra: a rare and usually indolent lesion distinct from prostatic adenocarcinoma.
  • [MeSH-major] Adenoma / pathology. Diverticulum / pathology. Prostatic Neoplasms / pathology. Urethral Neoplasms / pathology
  • [MeSH-minor] Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17886106.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


57. Sitdykova ME, Zubkov AIu: [Efficacy of vitaprost forte in the treatment of prostatic adenoma]. Urologiia; 2009 Nov-Dec;(6):27-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of vitaprost forte in the treatment of prostatic adenoma].
  • Thirty patients with a documented diagnosis of prostatic adenoma were treated with vitaprost forte (100 mg rectal suppositoria) for 60 days.
  • Its efficacy was proved by improved urodynamics of the lower urinary tract, reduction of prostatic size.
  • Vitaprost forte is recommended for treatment of patients suffering from prostatic adenoma with mild and moderate symptoms.
  • [MeSH-major] Peptides / administration & dosage. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169719.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Peptides; 0 / Vitaprost
  •  go-up   go-down


58. Miariatskas G, Aliakna V, Cheremnykh E: [Prevalence of enuresis in old males according to questionnaire data]. Urologiia; 2007 Mar-Apr;(2):21-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The risk to develop continuous incontinence grows in the presence of Parkinson's disease (OR = 3.50; 95% CI = 1.01-12.23), prostatic adenoma (OR = 5.29; 95% CL = 2.91-9.65).

  • MedlinePlus Health Information. consumer health - Bedwetting.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17578196.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


59. Morozov AP, Trapeznikov MF, Kushlinskiĭ NE: [Protein of type 1 binding insulin-like growth factors in blood serum in cancer and prostatic adenoma]. Urologiia; 2007 Mar-Apr;(2):50-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Protein of type 1 binding insulin-like growth factors in blood serum in cancer and prostatic adenoma].
  • We compared serum levels of insulin-like growth factors (IGF) type 1 protein (IGFP-1) in prostatic cancer (PC) and prostatic adenoma (PA).
  • Sensitivity and specificity of IGFP-1 estimation for differential diagnosis of PC were 72.1 and 57.1%, respectively), of IGFP-1/PSA for differential diagnosis was 81.3 and 87.5%, respectively.
  • [MeSH-major] Biomarkers, Tumor / blood. Insulin-Like Growth Factor Binding Protein 1 / blood. Prostatic Hyperplasia / diagnosis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17580387.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Insulin-Like Growth Factor Binding Protein 1; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


60. Bałdys-Waligórska A, Krzentowska A, Gołkowski F, Sokołowski G, Hubalewska-Dydejczyk A: The prevalence of benign and malignant neoplasms in acromegalic patients. Endokrynol Pol; 2010 Jan-Feb;61(1):29-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prevalence of benign and malignant neoplasms in acromegalic patients.
  • INTRODUCTION: In acromegalic patients, the prevalence of certain benign and malignant neoplasms is higher than that in the healthy population.
  • RESULTS: In the studied group of patients, we found the following prevalence of various tumours: nodular goitre - 64/101 patients (63.0%), polyps of the colon - 13/101 patients (13.0%); uterine polyps - 4/101 patients (4.0%); and prostate adenoma - 2/101 patients (2.0%).
  • [MeSH-minor] Adenoma / epidemiology. Adult. Aged. Aged, 80 and over. Colonic Polyps / epidemiology. Comorbidity. Female. Goiter / epidemiology. Humans. Male. Middle Aged. Pituitary Neoplasms / epidemiology. Poland / epidemiology. Prevalence. Prostatic Neoplasms / epidemiology. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205101.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


61. Tkachuk VN, Tkachuk IN: [Vitaprost forte efficacy in patients with prostatic adenoma]. Urologiia; 2008 Jul-Aug;(4):34-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vitaprost forte efficacy in patients with prostatic adenoma].
  • Efficacy and safety of a new bioregulatory peptide vitaprost forte was studied in 30 patients with prostatic adenoma.
  • It is shown that this drug relieves clinical symptoms of the disease, improves quality of life, uroflowmetric parameters, reduces the size of the prostatic gland.
  • Vitaprost forte is more effective in patients with prostatic adenoma combined with chronic prostatitis.
  • [MeSH-major] Peptides / administration & dosage. Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy
  • [MeSH-minor] Aged. Chronic Disease. Humans. Male. Middle Aged. Organ Size / drug effects. Prostate / pathology. Prostate / physiopathology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19058362.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Peptides; 0 / Vitaprost
  •  go-up   go-down


62. Tkachuk VN, Al'-Shukri SKh, Tkachuk IN: [Finasteride preoperative preparation of patients with prostatic adenoma to transurethral prostatic resection]. Urologiia; 2008 Jan-Feb;(1):27, 29, 31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Finasteride preoperative preparation of patients with prostatic adenoma to transurethral prostatic resection].
  • Finasteride effect before transurethral resection (TUR) of the prostatic gland was studied in 88 patients with prostatic adenoma (PA).
  • Finasteride reduced blood flow in prostatic tissue, density of the vascular plexus, epithelium/stroma coefficient from 1.26 to 0.84.
  • [MeSH-major] Blood Loss, Surgical / prevention & control. Enzyme Inhibitors / administration & dosage. Finasteride / administration & dosage. Preoperative Care. Prostate / surgery. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. FINASTERIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18652018.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 57GNO57U7G / Finasteride
  •  go-up   go-down


63. Davis A, Goel S, Picolos M, Wang M, Lavis V: Pituitary apoplexy after leuprolide. Pituitary; 2006;9(3):263-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinically unsuspected pituitary adenomas are common among adults on autopsy and MRI survey.
  • We report a case of a 61-year-old male patient with locally advanced prostate cancer who presented with an acute picture of pituitary apoplexy after his first dose of leuprolide.
  • Initial stimulatory effects of gonadotropin releasing hormone (GnRH) analogue may induce apoplexy in patients with asymptomatic gonadotroph adenomas.
  • [MeSH-major] Adenoma / complications. Antineoplastic Agents, Hormonal / adverse effects. Gonadotropin-Releasing Hormone / agonists. Leuprolide / adverse effects. Pituitary Apoplexy / chemically induced. Pituitary Neoplasms / complications. Prostatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. LEUPROLIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1990 Dec;144(6):1479-80 [2122011.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Apr;15(4):675-9 [8010269.001]
  • [Cites] Clin Endocrinol (Oxf). 1996 Jan;44(1):121-4 [8706284.001]
  • [Cites] J Endocrinol Invest. 1997 Oct;20(9):566-8 [9413812.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Jul;80(7):2267-8 [7608291.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2001 Oct;71(4):542-5 [11561045.001]
  • [Cites] Intern Med J. 2001 Jul;31(5):313-4 [11512605.001]
  • [Cites] Radiology. 1994 Oct;193(1):161-4 [8090885.001]
  • [Cites] Neurosurgery. 1984 Mar;14(3):363-73 [6369168.001]
  • [Cites] Lancet. 1995 Feb 18;345(8947):458 [7853980.001]
  • [Cites] N Engl J Med. 1991 Jan 10;324(2):93-103 [1984190.001]
  • [Cites] Acta Endocrinol (Copenh). 1984 Oct;107(2):149-54 [6437103.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 Aug;51(2):181-8 [10468988.001]
  • (PMID = 16832587.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 33515-09-2 / Gonadotropin-Releasing Hormone; EFY6W0M8TG / Leuprolide
  •  go-up   go-down


64. Cabello Benavente R, Jara Rascón J, Monzó JI, López Díez I, Subirá Ríos D, Lledó García E, Herranz Amo F, Hernández Fernández C: [Volume determinations of the whole prostate and of the adenoma by transrectal ultrasound: correlation with surgical specimen]. Actas Urol Esp; 2006 Feb;30(2):175-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Volume determinations of the whole prostate and of the adenoma by transrectal ultrasound: correlation with surgical specimen].
  • [Transliterated title] Correlación ecográfico-anatómica de la medición del volumen prostático total y de la zona transicional mediante ecografía transrectal.
  • OBJECTIVE: We evaluated whether preoperative transrecta ultrasound (TRUS) mesaurements of the transition zone (TZ) and total prostate volumen predict real prostatic weight.
  • MATERIAL AND METHODS: We compare estimated TRUS volumes with surgical specimen weight, in surgically treated patients with localized prostate cancer (group A, n = 33) or benign prostatic hyperplasia (group B, n = 37).
  • Both measurements were compared with surgical specimen weight, assuming 1 as specific prostate weight.
  • RESULTS: Group A: mean prostate measured volume was 38.6 cc. (SD 22.7), mean RP specimen weight was 54,2 g (SD 27.2) (p = 0.001).
  • Total estimated prostate volume underestimated prostatectomy specimen weight by 29%.
  • In order to adequate the estimated volume to the specimen weight, we calculated the formula: estimated prostate weight = 0.95 x prostatic measured volume + 17,657 (p = 0.005).
  • [MeSH-major] Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / ultrasonography. Prostatic Neoplasms / pathology. Prostatic Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16700208.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


65. Coletti Moja M, Milano E, Gasverde S, Gianelli M, Giordana MT: Olanzapine therapy in hallucinatory visions related to Bonnet syndrome. Neurol Sci; 2005 Jul;26(3):168-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No cognitive impairment and no diseases apart from prostatic adenoma treated with alpha-lythic therapy were reported.

  • MedlinePlus Health Information. consumer health - Eye Diseases.
  • MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.
  • Hazardous Substances Data Bank. Olanzapine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086130.001).
  • [ISSN] 1590-1874
  • [Journal-full-title] Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  • [ISO-abbreviation] Neurol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 12794-10-4 / Benzodiazepines; 132539-06-1 / olanzapine
  •  go-up   go-down


66. Gomberg VG, Nad' IuT: [Efficacy of Vitaprost Forte in the treatment of adenoma]. Urologiia; 2010 Sep-Oct;(5):35-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of Vitaprost Forte in the treatment of adenoma].
  • Pharmacotherapy with vitaprost forte was given to 40 patients with prostatic adenoma aged 55 to 77 years (mean age 67.6 +/- 0.9 years).
  • [MeSH-major] Peptides / administration & dosage. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21254638.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Peptides; 0 / Suppositories; 0 / Vitaprost
  •  go-up   go-down


67. Trapeznikova MF, Urenkov SB, Zubrilina NM, Podoĭnitsyn AA: [Current trends in the treatment of urological patients with transplanted kidney]. Urologiia; 2009 Mar-Apr;(2):9-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most of the patients had urolithiasis, prostatic adenoma, some patients had renal cyst, implanted kidney tumor, tumor of the arteriosclerotic kidneys, posterior urethra stricture, posterior urethra valve.
  • Kidney recipients with prostatic adenoma (2 and 5 years after transplantation) in 3 cases were subjected to scheduled TUR because of manifest obstructive symptoms.
  • Urethral nitinol stenting was made in one patient with AUR and prostatic size over 60 cm3, TUR was made 4 months later.
  • Prostatic adenoma is treated, as a rule, surgically (TUR of the prostate).
  • [MeSH-major] Kidney Transplantation. Prostatic Hyperplasia / therapy. Urologic Diseases / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526868.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


68. Pushkar' DIu, Dul'kin LM, Pletner DL, Bormotin AV, Liaginskiĭ AB: [Advanced microwave thermotherapy (PLFT) as a method of choice in the treatment of complicated, inoperable prostatic adenoma]. Urologiia; 2009 Nov-Dec;(6):22-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advanced microwave thermotherapy (PLFT) as a method of choice in the treatment of complicated, inoperable prostatic adenoma].
  • The aim of our study was assessment of efficacy of PLFT technique on ProstaLund CoreTHerm unit in nanagement of acute urine retention in patients with prostatic adenoma.
  • We treated 31 patients with prostatic adenoma (age 58-97, mean age 74 years, volume of the prostatic gland from 32 to 188 ml); 11 patients had suprapubic fistula, 8 carried urethral catheter for acute urinary retention.
  • PLFT destroyed 15 +/- 5% prostatic tissue in each of the treated patients.
  • Thus, PLFT is a highly effective and save treatment of prostatic adenoma and can be recommended as a standard management of patients with acute urinary retention at high surgical risk.
  • [MeSH-major] Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / therapy. Recovery of Function. Transurethral Resection of Prostate / methods. Urination

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169717.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


69. Sunil K, Menon R, Goel N, Sanghvi D, Bandgar T, Joshi SR, Menon P, Shah N, Goel A: Pituitary tuberculosis. J Assoc Physicians India; 2007 Jun;55:453-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tuberculous involvement of pituitary is extremely rare and is usually not suspected while dealing with pituitary adenomas, even in patients with history of systemic tuberculosis.
  • We report a case of pituitary tuberculoma in a patient who was undergoing treatment for prostatic tuberculosis.
  • Although diagnosis of sellar tuberculomas is difficult on clinical and radiological examinations, pituitary tuberculomas should be considered in the differential diagnosis of suprasellar masses, especially in developing countries as the condition is potentially curable with antituberculous treatment.
  • [MeSH-major] Pituitary Diseases / diagnosis. Sella Turcica / microbiology. Tuberculoma, Intracranial / diagnosis
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male. Prostate / microbiology. Prostate / pathology. Tuberculosis, Male Genital / diagnosis

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Pituitary Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17879504.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


70. Aslamazov EG, Akhvlediani ND, Vinarov AZ, Aliaev IuG: [Cernilton in the treatment of prostatic adenoma and chronic prostatitis]. Urologiia; 2007 Jan-Feb;(1):52, 54-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cernilton in the treatment of prostatic adenoma and chronic prostatitis].
  • The efficacy of the drug cernilton was studied in patients with prostatic adenoma (PA) and chronic bacterial prostatitis (CBP).
  • [MeSH-major] Plant Extracts / therapeutic use. Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy

  • Genetic Alliance. consumer health - Prostatitis.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17472001.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Plant Extracts; 8054-43-1 / cernilton
  •  go-up   go-down


71. Sotelo R, Clavijo R, Carmona O, Garcia A, Banda E, Miranda M, Fagin R: Robotic simple prostatectomy. J Urol; 2008 Feb;179(2):513-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Minimally invasive approaches for large, symptomatic benign prostatic hyperplasia are replacing the gold standard open surgical approach, duplicating its results with lower morbidity.
  • Considerable improvement from baseline was noted in International Prostate Symptom Score (preoperative vs postoperative 22 vs 7.25) and maximum urine flow (preoperative vs postoperative 17.75 vs 55.5 ml per minute).
  • Further publications are expected with larger series and larger prostatic adenomas.
  • [MeSH-major] Laparoscopy. Prostatectomy / methods. Prostatic Hyperplasia / surgery. Robotics

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2008 Oct;180(4):1569-70; author reply 1570 [18718613.001]
  • (PMID = 18076926.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Apolikhin OI, Sivkov AV, Beshliev DA, Abdullin II: [Current opportunities of pharmacotherapy of prostatic adenoma]. Urologiia; 2010 Mar-Apr;(2):54-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current opportunities of pharmacotherapy of prostatic adenoma].
  • [MeSH-major] 5-alpha Reductase Inhibitors / therapeutic use. Adrenergic alpha-Antagonists / therapeutic use. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20967996.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Lectures
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Adrenergic alpha-Antagonists
  •  go-up   go-down


73. Al'-Shukri SKh, Amdiĭ RE: [Value of combined urodynamic examination of patients with unsatisfactory outcomes of surgical treatment of prostatic adenoma]. Urologiia; 2006 Jul-Aug;(4):11-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Value of combined urodynamic examination of patients with unsatisfactory outcomes of surgical treatment of prostatic adenoma].
  • Forty three patients with unsatisfactory outcomes of surgical treatment of benign prostatic hyperplasia (BPH) were examined urodynamically.
  • Accurate diagnosis of characteristics and causes of lower urinary tracts dysfunction decides choice of adequate therapeutic policy.
  • [MeSH-major] Prostatectomy / adverse effects. Prostatic Hyperplasia / surgery. Urination Disorders / diagnosis. Urodynamics / physiology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17058672.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


74. Sow M, Nkégoum B, Oyono JL, Garoua, Nzokou A: [Epidemiological and histological features of urogenital tumours in Cameroon]. Prog Urol; 2006 Feb;16(1):36-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: A total of 2,371 urogenital tumours were identified, corresponding to 520 prostatic adenocarcinomas, 1,066 cases of benign prostatic hyperplasia, 41 testicular tumours (9 seminomatous tumours, 7 non-seminomatous tumours, 18 lymphomas, 4 benign papillomas and 2 rhabdomyosarcomas of the spermatic cord), 169 bladder tumours (25 transitional cell carcinomas, 70 squamous cell carcinomas, 67 adenocarcinomas, 2 lymphomas, 1 sarcoma and 1 benign papilloma), and 136 kidney tumours (20 Wilms tumours, 87 renal cell carcinomas, 6 transitional cell carcinomas, 16 lymphomas, 2 other malignant tumours and 5 adenomas).
  • CONCLUSION: Urogenital tumours in Cameroon are dominated by prostatic tumours.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16526537.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


75. Martov AG, Merinov DS, Kornienko SI, Gushchin BL, Ergakov DV, Mustafaev EM, Borisenko EA: [Postoperative urological complications of transurethral electrosurgical interventions on the prostate for adenoma]. Urologiia; 2006 Mar-Apr;(2):25-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative urological complications of transurethral electrosurgical interventions on the prostate for adenoma].
  • The aim of the study was comparison of urological complications after transurethral resection and its low-invasive alternatives: vaporization, rotoresection, vaporization resection, prostatic incision.
  • Case histories were studied of 5401 patients operated endoscopically for prostatic adenoma in 1991-2003.
  • No hemorrhagic complications occurred in rotoresection, no hemotransfusions were made in vaporization and vaporizing resection, prostatic incision was complicated by hemorrhage only in 0.9% cases.
  • [MeSH-major] Electrosurgery. Postoperative Complications / diagnosis. Postoperative Hemorrhage / diagnosis. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate
  • [MeSH-minor] Humans. Infection / diagnosis. Infection / therapy. Male. Prostatectomy / methods. Treatment Outcome. Urinary Bladder Diseases / diagnosis. Urinary Bladder Diseases / therapy

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16708585.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


76. Yang FY, Xing NZ, Wang JW, Zhang JH, Guo YL: [Retropublic extraperitoneal laparoscopic prostatectomy with urethra preservation]. Beijing Da Xue Xue Bao; 2010 Aug 18;42(4):469-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To explore the feasibility and superiority of retropubic extraperitoneal laparoscopic simple prostatectomy with prostatic urethra preservation to treat large volume benign prostatic hyperplasia(BPH) .
  • METHODS: From January 2006 to August 2009, laparoscopic simple prostatectomy with prostatic urethra preservation was performed in 45 patients with symptomatic BPH,and the age of patients was 70.5+/-7.2 (range 47 to 83) years old.
  • The transrectal ultrasound (TRUS) revealed BPH and calculated prostatic gland weight was 126.1+/-52.4 (range 62 to 365) g.
  • The technique included retropubic extraperitoneal space produced by balloon dilation, five trocars in a reverted U shape placed,transverse prostatic capsular incision made, subcapsular plane developed, prostatic adenoma removed while prostatic urethra preserved as well as prostatic capsule sutured.
  • Significant improvement was noted in the maximum flow rate, the International Prostate Score Symptoms (IPSS) and the quality of life questionnaires (QOL) three months after surgery.
  • CONCLUSION: Laparoscopic simple prostatectomy with prostatic urethra preservation for large benign prostatic hyperplasia is feasible and reproducible.
  • [MeSH-major] Laparoscopy / methods. Prostatectomy / methods. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20721267.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


77. Aliaev IuG, Apolikhin OI, Mazo EB, Vinarov AZ, Lokshin KL, Medvedev AA, Permiakova OV, Spivak LG, Shkol'nikov ME: [Efficacy and safety of prostamol-UNO in the treatment of patients with initial symptoms of prostatic adenoma and risk of progression: 2 years of investigations]. Urologiia; 2009 Jul-Aug;(4):36-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and safety of prostamol-UNO in the treatment of patients with initial symptoms of prostatic adenoma and risk of progression: 2 years of investigations].
  • The article presents 2-year pilot results of a multicenter, randomized, controlled trial of prostamol-UNO effects on symptoms progression, quality of life, tolerance and safety in patients with early prostatic adenoma.
  • Measurements were also made of changes in Qmax, urine volume, residual urine, size of the prostate.
  • [MeSH-major] Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19824382.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Plant Extracts; 0 / Prostamol-Uno
  •  go-up   go-down


78. Hiraoka Y, Shimizu Y, Iwamoto K, Takahashi H, Abe H: Trial of complete detachment of the whole prostate lobes in benign prostate hyperplasia by transurethral enucleation of the prostate. Urol Int; 2007;79(1):50-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trial of complete detachment of the whole prostate lobes in benign prostate hyperplasia by transurethral enucleation of the prostate.
  • INTRODUCTION: We tried a complete detachment of the whole prostate lobes for benign prostate hyperplasia (BPH) by transurethral enucleation of the prostate (TUE).
  • MATERIALS AND METHODS: For 46 BPH cases the whole prostate lobes were detached from the surgical capsule completely by a prostate-detaching blade and resectoscope beak, and dropped into the bladder.
  • The detached prostate lobes were removed by a soft tissue morcellator.
  • The preoperative total prostate and adenoma volume by transabdominal ultrasound measurement (TAUS) were 47.75 +/- 25.63 and 27.8 +/- 17.33 ml.
  • RESULTS: In all 46 BPH cases, the whole prostate lobes could be detached completely without a perforation.
  • Postoperative prostate volume and PSA were decreased to 9.56 ml and 0.8 ng/ml with complete removal of an adenoma.
  • CONCLUSIONS: TUDP could achieve complete removal of even a large adenoma without perforation, transurethral resection syndromes and blood transfusion safety.
  • [MeSH-major] Prostate / surgery. Prostatectomy / methods. Prostatic Hyperplasia / surgery


79. Baumert H, Ballaro A, Dugardin F, Kaisary AV: Laparoscopic versus open simple prostatectomy: a comparative study. J Urol; 2006 May;175(5):1691-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Laparoscopic simple prostatectomy has recently been developed to remove large prostatic adenomas causing bladder outflow obstruction.
  • A Millin and a transvesical-prostatic technique were used in the laparoscopic group and a transvesical technique was used in the open group.
  • RESULTS: There was no significant difference in prostatic size, patient age or body mass index between the 2 groups.
  • In the laparoscopic group the mean International Prostate Symptom score +/- SD improved from 22.4 +/- 6.9 to 5.7 +/- 3.6 and the urinary flow rate improved from 8.1 +/- 2.5 to 24.6 +/- 12.1 ml per minute (each p <0.001).
  • Further studies are indicated to determine whether this technique should be considered the treatment of choice for prostatic adenomas too large for safe endoscopic resection.
  • [MeSH-major] Laparoscopy. Prostatectomy / methods. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16600732.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Moran CA, Suster S: Primary parathyroid tumors of the mediastinum: a clinicopathologic and immunohistochemical study of 17 cases. Am J Clin Pathol; 2005 Nov;124(5):749-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of 17 patients, 13 had clinical primary hyperparathyroidism, 1 had secondary hyperparathyroidism due to polycystic kidney disease, and 1 had a history of prostatic carcinoma and 1 of chronic obstructive pulmonary disease.
  • Histologically, 2 tumors showed features of parathyroid carcinoma, and 15 tumors showed more conventional features of parathyroid adenomas.
  • Immunohistochemical studies for chromogranin, synaptophysin, low-molecular-weight keratin (CAM 5.2), and parathyroid hormone were performed in 10 cases (8 parathyroid adenomas and 2 parathyroid carcinomas).
  • The cases highlight the importance of keeping primary parathyroid tumors in the differential diagnosis of anterior mediastinal tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16203274.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Furuya S, Furuya R, Ogura H, Shimamura S, Araki T: [Transurethral resection for prostatic adenoma larger than 100 ml--preoperative treatment with interstitial laser coagulation of the prostate plus chlormadinone acetate as a treatment maneuver for safer operations]. Hinyokika Kiyo; 2005 Mar;51(3):159-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transurethral resection for prostatic adenoma larger than 100 ml--preoperative treatment with interstitial laser coagulation of the prostate plus chlormadinone acetate as a treatment maneuver for safer operations].
  • Between August 1985 and March 2004, we performed transurethral resection of the prostate (TURP) in 18 patients with benign prostatic hyperplasia (BPH) whose prostatic volume was larger than 100 ml.
  • Group A consisted of a total of 14 cases: 10 cases whose mean prostate volume was 114 ml (100 to 137 ml) and 4 cases whose prostate volume was not measured before TURP but whose mean resected prostatic tissue weight was 113 g (105 to 118 g).
  • Group B consisted of 4 cases whose mean prostate volume was 110 ml (101 to 133 ml).
  • Patients in group B underwent interstitial laser coagulation of the prostate (ILCP) followed by oral chlormadinone acetate (CMA) therapy (50 mg/day); TURP was performed 6 months later, once the prostate volume had shrunk to an average of 76 ml (66 to 91 ml).
  • [MeSH-major] Chlormadinone Acetate / administration & dosage. Laser Coagulation. Preoperative Care. Prostate / pathology. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate / methods

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. CHLORMADINONE ACETATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15852668.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0SY050L61N / Chlormadinone Acetate
  • [Number-of-references] 24
  •  go-up   go-down


82. Kamalov AA, Osmolovskiĭ BE: [Transurethral photoselective laser vaporization in the treatment of prostatic adenoma]. Urologiia; 2008 Sep-Oct;(5):28-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transurethral photoselective laser vaporization in the treatment of prostatic adenoma].
  • Progress in laser technologies allowed development of a highly effective method of laser adenomectomy--photoselective vaporization of the prostate (PSVP).
  • [MeSH-major] Laser Therapy / instrumentation. Laser Therapy / methods. Prostatic Hyperplasia / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19069492.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


83. Xiao GQ, Burstein DE, Miller LK, Unger PD: Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma. Arch Pathol Lab Med; 2006 Jun;130(6):805-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma.
  • CONTEXT: Nephrogenic adenoma is a rare benign lesion of the urinary tract.
  • Owing to its strong association with a history of urinary tract irritation, nephrogenic adenoma was initially thought to originate from urothelial metaplasia; however, no solid proof of this association has been found.
  • In addition to its uncertain origin, there can be diagnostic difficulty in distinguishing nephrogenic adenoma from prostatic carcinoma, particularly when dealing with lesions from the prostatic urethra.
  • OBJECTIVE: To elucidate a possible histogenic relationship between nephrogenic adenoma and renal tubules, and also to evaluate the role of immunohistochemistry in the diagnostic distinction between nephrogenic adenoma and prostate carcinoma.
  • DESIGN: Immunohistochemical studies were performed for P504S, prostate-specific antigen, CD10, p63, and epithelial membrane antigen on 9 cases of nephrogenic adenoma, 10 cases of normal renal parenchyma, and 10 cases of prostatic tissue, both benign and malignant.
  • RESULTS: Nephrogenic adenoma shares the same immunohistochemical profile as distal renal tubules: both are positive for P504S and epithelial membrane antigen and negative for p63, CD10, and prostate-specific antigen.
  • Prostatic adenocarcinoma tissue was positive for P504S and prostate-specific antigen, and normal prostatic gland tissue was positive for prostate-specific antigen and negative for P504S; p63-stained basal cells in normal prostatic gland tissue but did not react with prostatic adenocarcinoma tissue.
  • The CD10 inconsistently stained normal and neoplastic prostatic gland tissue.
  • Epithelial membrane antigen stain was negative in prostatic carcinoma, with rare occasional reactivity in normal prostatic glands.
  • CONCLUSION: These findings provide supporting evidence that nephrogenic adenoma is derived from distal renal tubules.
  • Our results also demonstrated that the combination of P504S and prostate-specific antigen with epithelial membrane antigen is a valuable tool in distinguishing prostatic carcinoma from nephrogenic adenoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Immunohistochemistry / methods. Prostatic Neoplasms / diagnosis. Urologic Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Male. Mucin-1 / analysis. Racemases and Epimerases / analysis. Urothelium / chemistry. Urothelium / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740031.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


84. John H, Bucher C, Engel N, Fischer B, Fehr JL: Preperitoneal robotic prostate adenomectomy. Urology; 2009 Apr;73(4):811-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preperitoneal robotic prostate adenomectomy.
  • OBJECTIVES: To describe the surgical technique and evaluate the feasibility of robotic-assisted preperitoneal prostate adenomectomy for large benign adenomas in a pilot series.
  • CONCLUSIONS: The results of our study have shown that preperitoneal robotic transvesical prostate adenomectomy is a feasible and reproducible procedure.
  • Additional series with larger patient cohorts and prostate adenomas are needed.
  • [MeSH-major] Prostatectomy / methods. Prostatic Hyperplasia / surgery. Robotics

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19195694.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Pushkar' DIu, belousov IuB, Dukhanin AS, Maneshina OA, Govorov AV, Kurdzhiev MA: [Interaction of omnic (tamsulozine) and its generic analogues with alpha-adrenoreceptors]. Urologiia; 2009 Sep-Oct;(5):36-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In current practice of pharmacotherapy of prostatic adenoma alpha1-adrenoblockers are first-line drugs the efficacy and safety of which have been proved in many randomized studies.
  • Because of the appearance of a large amount of generic analogues of tamsulozine on the market we studied the ability of tamsulozine analogues to bind with alpha-adrenoreceptors on rat and human prostate affected by adenoma.
  • [MeSH-major] Adenoma / metabolism. Adenoma / microbiology. Adrenergic alpha-Antagonists / pharmacokinetics. Drugs, Generic / pharmacokinetics. Prostate / metabolism. Receptors, Adrenergic, alpha / metabolism. Sulfonamides / pharmacokinetics

  • Hazardous Substances Data Bank. Tamsulosin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20209868.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Drugs, Generic; 0 / Receptors, Adrenergic, alpha; 0 / Sulfonamides; G3P28OML5I / tamsulosin
  •  go-up   go-down


86. Neĭmark AI, Snegirev IV, Neĭmark BA: [Transrectal magnetotherapy of the prostate from Intramag device in prophylaxis of postoperative complications of transurethral resection of prostatic adenoma]. Urologiia; 2006 Mar-Apr;(2):75, 77-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transrectal magnetotherapy of the prostate from Intramag device in prophylaxis of postoperative complications of transurethral resection of prostatic adenoma].
  • The authors analyse preoperative preparation of 91 patients with benign prostatic hyperplasia (BPH).
  • Two groups of patients received conventional preparation (group 1) and magnetotherapy (group 2) before TUR of the prostate.
  • The examination covered immune system, bacteriological indices of urine and prostatic tissue.
  • Conventional preoperative preparation fails to correct immunity, to change bacterial urine flora, to improve hemodynamics in the prostate.
  • [MeSH-major] Ferrosoferric Oxide / therapeutic use. Physical Therapy Modalities / instrumentation. Postoperative Complications / prevention & control. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate. Urinary Tract Infections / prevention & control
  • [MeSH-minor] B-Lymphocytes / immunology. Humans. Leukocyte Count. Male. Perioperative Care / methods. Prostate / microbiology. Rectum. T-Lymphocytes / immunology. Urine / microbiology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Urinary Tract Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16708596.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] XM0M87F357 / Ferrosoferric Oxide
  •  go-up   go-down


87. Shkol'nikov ME, Iakushkin VR: [Diagnosis and treatment of nocturia in patients with prostatic adenoma]. Urologiia; 2008 Nov-Dec;(6):75-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of nocturia in patients with prostatic adenoma].
  • [MeSH-major] Nocturia / diagnosis. Nocturia / therapy. Prostatic Hyperplasia / diagnosis. Prostatic Hyperplasia / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19248603.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Number-of-references] 63
  •  go-up   go-down


88. Helfand BT, Anderson CB, Fought A, Kim DY, Vyas A, McVary KT: Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia. Urology; 2009 Jul;74(1):177-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
  • OBJECTIVES: To determine whether prostate-specific antigen (PSA) values can distinguish those with prostate cancer (CaP) from those with histologic benign prostatic hyperplasia (BPH) only after surgical intervention.
  • Prostatic adenoma inevitably remains after BPH surgery; therefore, patients remain at risk of developing CaP.
  • METHODS: We performed a review of patients who had undergone transurethral resection of the prostate (TURP; n = 343), holmium laser resection of the prostate (HoLRP; n = 54), or open prostatectomy (OP; n = 68).
  • [MeSH-major] Prostate-Specific Antigen / blood. Prostatectomy. Prostatic Hyperplasia / surgery. Prostatic Neoplasms / blood. Prostatic Neoplasms / diagnosis


89. Kravchick S, Cytron S, Stepnov E, Ben-Dor D, Kravchenko Y, Peled R: 7 to 10 years' follow-up of 573 patients with elevated prostate-specific antigen (&gt;4 ng/mL) or/and suspected rectal examination: biopsies protocol and follow-up guides. J Endourol; 2009 Jun;23(6):1007-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 7 to 10 years' follow-up of 573 patients with elevated prostate-specific antigen (>4 ng/mL) or/and suspected rectal examination: biopsies protocol and follow-up guides.
  • PATIENTS AND METHODS: We included in this study 600 consecutive patients with suspicious findings on a per-rectum examination and/or an elevated prostate-specific antigen (PSA) (>4 ng/mL) level.
  • In all patients, we took from 8 to 16 biopsy samples, according to the prostate volume, from the lateral aspects.
  • TRUS-biopsy detected prostate cancer (PCa) in 257 patients (44.85% overall detection rate).
  • Prostate volumes were significantly smaller (52.9 +/- 22.4 cc vs 58.9 +/- 23.8 cc, P < 0.002) and the PSA/adenoma/prostate volumes ratio (ad-pro) ratio was higher (18.3 +/- 9 vs 13.96, P < 0/001) in the patients with PCa.
  • Patients with PCa underwent fewer biopsy procedures and biopsy sessions than patients without a diagnosis of PCa (14.9 +/- 8.9 vs 20.4 +/- 12, P < 0.001;1.3 +/- 0.6 vs 1.7 +/- 0.9, P < 0.001).
  • Numbers of biopsy procedures and PSA/ad-pro ratio were the strongest predictive factors for PCa detection (P < 0.001).
  • CONCLUSIONS: In patients with a prostate volume >or=53 cc and PSA/ad-pro ratio >or=18, the optimal biopsy cores should be >or=15.

  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19456240.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


90. Mazo EB, Krivoborodov GG, Shkol'nikov ME, Efremov NS: [Botulinic toxin of type A in the treatment of prostatic adenoma and cancer]. Urologiia; 2008 Jul-Aug;(4):63-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Botulinic toxin of type A in the treatment of prostatic adenoma and cancer].
  • [MeSH-major] Botulinum Toxins, Type A / therapeutic use. Neuromuscular Agents / therapeutic use. Prostatic Hyperplasia / drug therapy. Prostatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Botox.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19058365.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Neuromuscular Agents; EC 3.4.24.69 / Botulinum Toxins, Type A
  • [Number-of-references] 37
  •  go-up   go-down


91. Lanfranco F, Baldi M, Cassoni P, Bosco M, Ghé C, Muccioli G: Ghrelin and prostate cancer. Vitam Horm; 2008;77:301-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ghrelin and prostate cancer.
  • Several endocrine and nonendocrine cancer cells (pituitary adenomas; gastroenteropancreatic and pulmonary carcinoids; colorectal neoplasms, thyroid tumors; lung, breast, and pancreatic carcinomas) as well as their related cell lines have been shown able to express ghrelin both at mRNA and at protein level.
  • This chapter highlights the evidence for the expression of ghrelin and its receptors in one of the most frequent human malignancies, the prostate cancer, and information regarding their potential functional role in related cell lines.
  • [MeSH-major] Ghrelin / metabolism. Prostatic Neoplasms / metabolism. Receptors, Ghrelin / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17983862.001).
  • [ISSN] 0083-6729
  • [Journal-full-title] Vitamins and hormones
  • [ISO-abbreviation] Vitam. Horm.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ghrelin; 0 / Receptors, Ghrelin
  • [Number-of-references] 130
  •  go-up   go-down


92. Rehman J, Khan SA, Sukkarieh T, Chughtai B, Waltzer WC: Extraperitoneal laparoscopic prostatectomy (adenomectomy) for obstructing benign prostatic hyperplasia: transvesical and transcapsular (Millin) techniques. J Endourol; 2005 May;19(4):491-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraperitoneal laparoscopic prostatectomy (adenomectomy) for obstructing benign prostatic hyperplasia: transvesical and transcapsular (Millin) techniques.
  • PURPOSE: We describe extraperitoneal laparoscopic resection of large prostatic adenomas (<100 g) as an alternative to open simple prostatectomy by both the transcapsular or Millin and the transvesical approaches.
  • PATIENTS AND METHODS: We have performed more than 20 laparoscopic prostatectomies (adenomectomies) for benign prostatic hyperplasia (BPH) for glands >100 g.
  • Using an extraperitoneal approach, enucleation of the obstructing prostatic lobes was performed with the aid of a Harmonic Scalpel and laparoscopic claw forceps.
  • The adenoma removed was approximately 138 g in the first case and 102 g in the second case.


93. Jenkins PJ: Cancers associated with acromegaly. Neuroendocrinology; 2006;83(3-4):218-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • More recently, it has become apparent that patients with acromegaly may also have an increased prevalence of colorectal adenomas and cancer.
  • There is some evidence to suggest that breast and prostatic malignancies might also be increased in acromegaly.
  • [MeSH-major] Acromegaly / complications. Breast Neoplasms / etiology. Colorectal Neoplasms / etiology. Prostatic Neoplasms / etiology
  • [MeSH-minor] Adenoma / blood. Adenoma / epidemiology. Adenoma / etiology. Carcinoma / blood. Carcinoma / epidemiology. Carcinoma / etiology. Female. Human Growth Hormone / blood. Humans. Male


94. Figueiredo JC, Grau MV, Haile RW, Sandler RS, Summers RW, Bresalier RS, Burke CA, McKeown-Eyssen GE, Baron JA: Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst; 2009 Mar 18;101(6):432-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Folic acid and risk of prostate cancer: results from a randomized clinical trial.
  • Data regarding the association between folate status and risk of prostate cancer are sparse and conflicting.
  • We studied prostate cancer occurrence in the Aspirin/Folate Polyp Prevention Study, a placebo-controlled randomized trial of aspirin and folic acid supplementation for the chemoprevention of colorectal adenomas conducted between July 6, 1994, and December 31, 2006.
  • Aspirin alone had no statistically significant effect on prostate cancer incidence, but there were marked differences according to folic acid treatment.
  • Among the 643 men who were randomly assigned to placebo or supplementation with folic acid, the estimated probability of being diagnosed with prostate cancer over a 10-year period was 9.7% (95% confidence interval [CI] = 6.5% to 14.5%) in the folic acid group and 3.3% (95% CI = 1.7% to 6.4%) in the placebo group (age-adjusted hazard ratio = 2.63, 95% CI = 1.23 to 5.65, Wald test P = .01).
  • In contrast, baseline dietary folate intake and plasma folate in nonmultivitamin users were inversely associated with risk of prostate cancer, although these associations did not attain statistical significance in adjusted analyses.
  • These findings highlight the potential complex role of folate in prostate cancer and the possibly different effects of folic acid-containing supplements vs natural sources of folate.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Aspirin / therapeutic use. Colorectal Neoplasms / prevention & control. Dietary Supplements. Folic Acid / therapeutic use. Prostatic Neoplasms / epidemiology. Vitamin B Complex / therapeutic use
  • [MeSH-minor] Adenoma / prevention & control. Aged. Aged, 80 and over. Cyclooxygenase Inhibitors / therapeutic use. Double-Blind Method. Follow-Up Studies. Humans. Incidence. Kaplan-Meier Estimate. Male. Middle Aged. Proportional Hazards Models. Research Design. Surveys and Questionnaires. United States / epidemiology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - B Vitamins.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Genet Metab. 2000 Sep-Oct;71(1-2):121-38 [11001804.001]
  • [Cites] Prostate. 2000 Dec 1;45(4):350-4 [11102961.001]
  • [Cites] J Nutr. 2002 Aug;132(8 Suppl):2413S-2418S [12163703.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):850-61 [12415255.001]
  • [Cites] J Nutr. 2003 Nov;133(11 Suppl 1):3731S-3739S [14608107.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1271-2 [14652294.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6357-62 [14695135.001]
  • [Cites] Eur J Cancer. 1997 Jan;33(1):101-7 [9071908.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2321-4 [9192800.001]
  • [Cites] Methods Enzymol. 1997;281:43-53 [9250965.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Jan 1;156(1):31-6 [15588853.001]
  • [Cites] Int J Cancer. 2005 Feb 20;113(5):819-24 [15499634.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):944-8 [15824168.001]
  • [Cites] Clin Chem. 2005 Jul;51(7):1206-16 [15976101.001]
  • [Cites] J Nutr. 2006 Jan;136(1):189-94 [16365081.001]
  • [Cites] Ann Epidemiol. 2006 Mar;16(3):206-12 [16343942.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):189-93 [16492904.001]
  • [Cites] Prostate. 2006 Jun 1;66(8):867-75 [16496414.001]
  • [Cites] Am J Epidemiol. 2006 Jun 1;163(11):989-96 [16554345.001]
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):243-50 [16453285.001]
  • [Cites] Am J Clin Nutr. 2006 Oct;84(4):929-35 [17023722.001]
  • [Cites] Am J Clin Nutr. 2007 Feb;85(2):465-73 [17284745.001]
  • [Cites] J Natl Cancer Inst. 2007 May 16;99(10):754-64 [17505071.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2351-9 [17551129.001]
  • [Cites] Oncogene. 2007 Oct 4;26(45):6560-5 [17486081.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):279-85 [18268110.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2136-45 [18708408.001]
  • [CommentIn] J Natl Cancer Inst. 2009 Mar 18;101(6):363-5 [19276449.001]
  • (PMID = 19276452.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA-059005; United States / NCI NIH HHS / CA / U54-CA-100971
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase Inhibitors; 12001-76-2 / Vitamin B Complex; 935E97BOY8 / Folic Acid; R16CO5Y76E / Aspirin
  • [Other-IDs] NLM/ PMC2657096
  •  go-up   go-down


95. Shin EJ, Chappell E, Pethe V, Hersey K, van der Kwast T, Fleshner N, Bapat B: MYH mutations are rare in prostate cancer. J Cancer Res Clin Oncol; 2007 Jun;133(6):373-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MYH mutations are rare in prostate cancer.
  • PURPOSE: Oxidative stress is considered a risk factor for prostate cancer development and is associated with the production of reactive oxygen species (ROS).
  • Inherited MYH mutations predispose to colorectal adenomas and cancer.
  • A compromised base-excision repair function due to defective MYH may contribute to prostate carcinogenesis.
  • Here, we examine the genetic contribution of MYH to prostate cancer risk.
  • METHODS: Patients diagnosed with high-grade prostatic intraepithelial neoplasia (HGPIN) alone (n = 45), prostate cancer alone (n = 123) or both (n = 82) were screened for the two most common mutations in the MYH gene using PCR-based RFLP analysis.
  • RESULTS: Biallelic germline mutations in MYH were not detected among prostate cancer patients.
  • CONCLUSIONS: MYH mutations are unlikely to contribute to prostate cancer risk.
  • [MeSH-major] DNA Glycosylases / genetics. Mutation. Prostatic Neoplasms / genetics

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7595-9 [14633673.001]
  • [Cites] Nat Genet. 2002 Feb;30(2):227-32 [11818965.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):9-16 [15236166.001]
  • [Cites] Am J Med Genet A. 2003 Aug 30;121A(2):159-62 [12910497.001]
  • [Cites] Trends Mol Med. 2002 Apr;8(4):179-86 [11927276.001]
  • [Cites] Lancet. 2003 Jul 5;362(9377):39-41 [12853198.001]
  • [Cites] Lancet Oncol. 2005 Aug;6(8):566-72 [16054567.001]
  • [Cites] Lancet. 2003 Mar 15;361(9361):955-64 [12648986.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 3;96(21):1631-4 [15523092.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Mar;132(3):159-62 [16292541.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109 (4):554-8 [14991577.001]
  • [Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]
  • [Cites] Hum Mol Genet. 2003 Oct 15;12 Spec No 2:R159-65 [12915454.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1000-8 [16702383.001]
  • [Cites] Fam Cancer. 2003;2(1):57-67 [14574167.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):827-32 [12937124.001]
  • [Cites] World J Gastroenterol. 2005 Mar 14;11(10):1481-8 [15770724.001]
  • [Cites] Ann N Y Acad Sci. 2001 Dec;952:135-44 [11795433.001]
  • [Cites] Am J Pathol. 2003 May;162(5):1545-8 [12707038.001]
  • [Cites] J Med Genet. 2005 Sep;42(9):e54 [16140997.001]
  • [Cites] Am J Gastroenterol. 2006 Jul;101(7):1591-6 [16863565.001]
  • [Cites] Hum Mol Genet. 2002 Nov 1;11(23):2961-7 [12393807.001]
  • [Cites] Nature. 1997 Apr 24;386(6627):761, 763 [9126728.001]
  • [Cites] Cancer Metastasis Rev. 2001;20(3-4):155-64 [12085959.001]
  • [Cites] Hum Genet. 2004 Jan;114(2):207-10 [14579148.001]
  • [Cites] Mol Carcinog. 2003 Mar;36(3):123-9 [12619034.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2253-7 [11956079.001]
  • [Cites] Genes Chromosomes Cancer. 2004 May;40(1):1-9 [15034862.001]
  • [Cites] N Engl J Med. 2003 Feb 27;348(9):791-9 [12606733.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):680-4 [14999774.001]
  • (PMID = 17219200.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / mutY adenine glycosylase
  •  go-up   go-down


96. Martov AG, Ergakov DV: [The experience in dutasteride use before transurethral prostatic resection for large adenoma]. Urologiia; 2008 Jul-Aug;(4):46, 48-50, 52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The experience in dutasteride use before transurethral prostatic resection for large adenoma].
  • Dutasterid is a novel effective inhibitor of 5-alpha reductase of both types which can be used in patients with large (more than 80 cm3) prostatic adenoma to prevent intra- and postoperative hemorrhagic complications before transurethral resection of the prostate (TUR).
  • The trial included 70 males aged 67-82 years (mean age 74 years) with large size prostatic adenoma (more than 80 cm3) having indications for prostatic TUR.
  • Patients with coagulopathy, suspected prostatic cancer, previous treatment with 5-alpha reductase inhibitors were not included.
  • We recommend to begin dutasterid administration in a dose 0.5 mg for 1 month before TUR not only for patients with larger prostate (greater than 80 cm3) but with smaller prostates (30-80 cm3) for prevention of hemorrhagic complications and better conditions for surgery.
  • [MeSH-major] Azasteroids / administration & dosage. Enzyme Inhibitors / administration & dosage. Preoperative Care. Prostatic Hyperplasia / surgery. Urogenital Surgical Procedures

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19054996.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Azasteroids; 0 / Enzyme Inhibitors; O0J6XJN02I / Dutasteride
  •  go-up   go-down


97. Shalekenov BU, Kuandykov EA, Anafin TG, Shalekenov SB: [Photoselective laser vaporization of complicated prostatic adenoma]. Urologiia; 2007 Nov-Dec;(6):73-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Photoselective laser vaporization of complicated prostatic adenoma].
  • The aim of the study was to determine indications for use of photoselective laser vaporization of the prostate (PVP) in clinical practice and to evaluate long-term results of this method.
  • Since September 2005 to February 2007 a total of 106 patients aged 55-95 years with prostatic adenoma were operated.
  • Photoselective laser vaporization improves quality of life in prostatic adenoma at all stages of the disease.
  • [MeSH-major] Laser Therapy. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18649665.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


98. Grigor'ev ME, Konorev VA: [Dutasteride--an inhibitor of 5alpha-reductase of type I and II--in the treatment of patients with prostatic adenoma. What is the latest news?]. Urologiia; 2007 Nov-Dec;(6):90, 92-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Dutasteride--an inhibitor of 5alpha-reductase of type I and II--in the treatment of patients with prostatic adenoma. What is the latest news?].
  • [MeSH-major] 5-alpha Reductase Inhibitors. Azasteroids / therapeutic use. Enzyme Inhibitors / therapeutic use. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18652016.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Azasteroids; 0 / Enzyme Inhibitors; EC 1.3.99.5 / 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; EC 1.3.99.5 / steroid-5alpha-reductase type 1; EC 1.3.99.5 / steroid-5alpha-reductase type 2; O0J6XJN02I / Dutasteride
  • [Number-of-references] 46
  •  go-up   go-down


99. Skolarikos A, Papachristou C, Athanasiadis G, Chalikopoulos D, Deliveliotis C, Alivizatos G: Eighteen-month results of a randomized prospective study comparing transurethral photoselective vaporization with transvesical open enucleation for prostatic adenomas greater than 80 cc. J Endourol; 2008 Oct;22(10):2333-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eighteen-month results of a randomized prospective study comparing transurethral photoselective vaporization with transvesical open enucleation for prostatic adenomas greater than 80 cc.
  • CONFLICT OF INTEREST: None Take Home Message: This is a prospective randomized study showing that for large prostatic adenomas, photoselective vaporization of the prostate requires less blood transfusions, shorter catheterization time and shorter hospital stay compared to open prostatectomy, while achieving similar functional results at the same time.
  • AIM: The effectiveness and the safety of photoselective vaporization of the prostate (PVP) was compared to that of open prostatectomy (OP) for the surgical treatment of large prostatic adenomas.
  • METHODS: 125 patients with prostate glands>80 ml, were randomly allocated to PVP (n=65) or OP (n=60) and prospectively evaluated at 1, 3, 6, 12, and 18 months postoperatively.
  • International prostate symptom score (IPSS) and peak urinary flow rate (Qmax) were chosen as primary treatment-related endpoints.
  • At three months prostate volume was significantly lower in the OP group and remained as such throughout follow-up.
  • CONCLUSIONS: Our results indicate that for an 18 month period photoselective vaporization of the prostate is a highly acceptable treatment alternative to open prostatectomy.

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18837655.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


100. Arbuliev MG, Zaĭnulabidov ZSh, Mukhamad II, Arbuliev KM: [A variant of transvesical extraurethral adenomectomy]. Urologiia; 2007 Jul-Aug;(4):37-9, 41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To facilitate extraurethral adenomectomy, we used a semicylindric scalpel and metallic tube (tubus) to make a semioval cut parallel to proximal prostatic portion of the urethra along the posterior semicircle of the bladder neck in 260 patients with prostatic adenoma (PA).
  • Extra-urethral adenomectomy with semicylindric scalpel injured prostatic urethra in lesser extent than endourethral adenomectomy, it reduced the risk of hemorrhage, entailed neither stricture of the posterior urethra nor incontinence of urine in the postoperative period.
  • [MeSH-major] Prostatic Hyperplasia / surgery. Urologic Surgical Procedures, Male / instrumentation. Urologic Surgical Procedures, Male / methods

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17915447.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down






Advertisement